



**HAL**  
open science

## **Eg5 targeting agents: From new anti-mitotic based inhibitor discovery to cancer therapy and resistance**

Isabel Garcia-Saez, Dimitrios A Skoufias

► **To cite this version:**

Isabel Garcia-Saez, Dimitrios A Skoufias. Eg5 targeting agents: From new anti-mitotic based inhibitor discovery to cancer therapy and resistance. *Biochemical Pharmacology*, 2021, 184, pp.114364. 10.1016/j.bcp.2020.114364 . hal-03454834

**HAL Id: hal-03454834**

**<https://cnrs.hal.science/hal-03454834v1>**

Submitted on 30 Nov 2021

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## **Eg5 Targeting Agents :**

### **From new anti-mitotic based inhibitor discovery to cancer therapy and resistance**

Isabel Garcia-Saez and Dimitrios A. Skoufias

#### **Affiliations:**

Université Grenoble Alpes, CNRS, CEA, Institut de Biologie Structurale (IBS), 38000 Grenoble,  
France

#### **Conflict of Interest**

The authors declare no competing interests.

\*Correspondence: [dimitrios.skoufias@ibs.fr](mailto:dimitrios.skoufias@ibs.fr)

## Abstract

Eg5, the gene product of *Kif11* gene, also known as kinesin spindle protein, is a motor protein involved in the proper establishment of a bipolar mitotic spindle. Eg5 is one of the 45 different kinesins coded in the human genome of the kinesin motor protein superfamily. Over the last three decades Eg5 has attracted great interest as a promising new mitotic target. The identification of monastrol as specific inhibitor of the ATPase activity of the motor domain of Eg5 inhibiting the Eg5 microtubule motility *in vitro* and *in cellulo* sparked an intense interest in academia and industry to pursue the identification of novel small molecules that target Eg5 in order to be used in cancer chemotherapy based on the anti-mitotic strategy. Several Eg5 inhibitors entered clinical trials. Currently the field is faced with the problem that most of the inhibitors tested exhibited only limited efficacy. However, one Eg5 inhibitor, Arry-520 (clinical name filanesib), has demonstrated clinical efficacy in patients with multiple myeloma and is scheduled to enter phase III clinical trials. At the same time, new trends in Eg5 inhibitor research are emerging, including an increased interest in novel inhibitor binding sites and a focus on drug synergy with established antitumor agents to improve chemotherapeutic efficacy. This review presents an updated view of the structure and function of Eg5-inhibitor complexes, traces the possible development of resistance to Eg5 inhibitors and their potential therapeutic applications, and surveys the current challenges and future directions of this active field in drug discovery.

## Keywords

Eg5

microtubules

antimitotic drugs

kinesin motors

drug discovery

## 1. Introduction

### 1.1 Functions of the kinesin motor Eg5 in mitotic spindle formation and maintenance

1 Eg5, also known as kinesin spindle protein or *Kif11*, was first identified as a protein coded by  
2 an mRNA which was specifically deadenylated and released from polysomes after *Xenopus* egg  
3 fertilization [1]. Based on the predicted amino acid sequence, the Eg5 protein was thought to  
4 be a member of the kinesin motor superfamily [2], a prediction which was further supported  
5 by the use of antibodies raised against short peptides with conserved amino acid sequences  
6 shared between members of the kinesin superfamily of motor proteins [3]. Further biochemical  
7 and cellular studies confirmed that indeed Eg5 was a spindle microtubule associated protein  
8 with a microtubule plus end directed motor activity [4] whose spindle association is dependent  
9 on phosphorylation of its C-terminus by Cdk1 [5]. The mitotic roles of Eg5 are not only limited  
10 in cross linking spindle microtubules but also recently extended in the regulation of  
11 microtubule-end dynamics due to its microtubule polymerase activity [6]. Additional non-  
12 nuclear functions for Eg5 are reported that include the transport of secretory proteins from the  
13 Golgi complex to the cell surface in non-mitotic cells [7], as well as the enhancement of  
14 translation by serving as a linker between ribosomes and microtubules [8]. Furthermore, in  
15 postmitotic neurons, Eg5 is involved in cell migration and in axonal and dendritic transport and  
16 morphology[9][10][11].

17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34 Eg5, as all members of the kinesin-5 family, self assembles into a homotetrameric minifilament,  
35 composed of two dimers arranged in an antiparallel fashion mediated by the assembly of a long  
36 central rod (Fig 1A). The two opposing ends of the mini filament are composed by the two  
37 globular N-terminal motor domains [12]. The motor domains convert the free energy of  
38 nucleoside 5'-triphosphate hydrolysis (typically ATP) into directed mechanical motion during  
39 their interaction with a microtubule track. Each Eg5 dimer is formed by a long alpha helical  
40 coiled coil that follows the motor domain [13]. The tetramer is assembled by the two dimers  
41 that built the central rod formed by four alpha helixes all intertwined with each other in  
42 antiparallel fashion [14]. Interestingly, the C-terminal tail domain of each of the Eg5 dimer has  
43 been shown to interact with the opposing N-terminal motor domain. Recently it was shown that  
44 the tail is capable to regulate the Eg5 motor activity by stabilizing the microtubule binding state  
45 by slowing the ATP binding resulting in high force production at both homotetramer ends [15].  
46 This slows the movement of Eg5, allowing Eg5 tetramers to cluster and work together,  
47 generating more force on microtubules.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 Furthermore, the opposing pairs of motors heads located at either end of the coiled-coil stalk  
2 could cooperate to enhance processivity. Based on the average run length for the dimer, and  
3 assuming each pair of dimers in the homotetramer moves independently, the tetramer should  
4 remain attached to the spindle for ~64 steps, on average [16].  
5  
6

7  
8 At the G2 to M transition, the tetrameric nature of Eg5, with two motor heads in each side allows  
9 Eg5 to engage and crosslink two antiparallel microtubules and move them in opposite  
10 directions, causing them to slide past each other, an activity necessary for the establishment of  
11 a bipolar spindle [4][5][17]. Lack of Eg5 activity either through motor activity inhibition [18]  
12 or depletion of the motor by RNAi [19][20] leads to failure of the separation of the duplicated  
13 centrosomes and the construction of a monoastral spindle leading to a mitotic block (Fig 1B).  
14  
15  
16  
17  
18  
19  
20

21 In previous work, a targeted null allele [21] and gene trap allele in *Kif11* (the gene coding for  
22 Eg5) produced no apparent phenotype when present in the heterozygotes state with a wild  
23 type (WT) allele, but caused pre-implantation embryonic lethality in the homozygous state  
24 [22]. Interestingly, through a number of exome sequencing studies of individuals diagnosed  
25 with Microcephaly Lymphedema Chorioretinoma Dysplasia (MLCRD) it became apparent that  
26 *Kif11* mutations are linked to this human syndrome [23]. The list of mutations in *Kif11* linked  
27 not only to MLCRD but also to the related syndrome microcephaly with or without  
28 chorioretinopathy, lymphedema, or mental retardation (MCLMR) (OMIM 152950), and to  
29 Familial Exudative Vitreoretinopathy (FEVR) [24] as well as to Molecular and cone/cone-rod  
30 dystrophies (MD/CCRD) [25]. In most cases, genetic analysis concluded that the mutations  
31 were inherited in an autosomal dominant manner. Expression analyses in chick embryos upon  
32 stimulation of *in vivo* angiogenesis with vascular endothelial growth factor-A (VEGF-A)  
33 indicated up-regulation of *Kif11* kinesin-encoding gene predominantly in lymphoblasts and  
34 endothelial cells [26]. In the same study, chemical inhibition of Eg5 activity blocked endothelial  
35 cell proliferation and migration *in vitro* and mitosis-independent vascular outgrowth in aortic  
36 ring cultures was strongly impaired. *In vivo*, interfering with *Kif11*/Eg5 function caused  
37 developmental and vascular defects in zebrafish and chick embryos and potent inhibition of  
38 tumor angiogenesis in experimental tumor models [26]. More recent studies aiming to explore  
39 the pathogenic basis of *Kif11*-associated retinal vascular disease, led to the generation of a  
40 conditional *Kif11* knockout mouse. Postnatal endothelial cells-specific knockout of *Kif11* was  
41 associated with a marked hypoplasia of the retinal vasculature and a milder hypoplasia of the  
42 cerebellar vasculature, implying that *Kif11* loss causes retarded retinal vascular development  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

[27]. The most rational explanation for the *Kif11* phenotype was that it reflects *Kif11*'s role in cell proliferation and, more specifically, in mitotic spindle dynamics during mitosis.

## **1.2 Eg5 as a valid target for the development of inhibitors for anti-mitotic drug therapy.**

Eg5 is expressed in CD34<sup>+</sup> cell, testis, cardiac muscle cell and some other human normal proliferation tissues. However, the expression level is significantly lower than that in malignant tissues. Overexpression of Eg5 leads to significant instability of the genome in mouse models and carcinogenesis. Studies have evaluated the Eg5 expression and its correlation with clinicopathological characteristics in various malignant tumors. For example, activation of Eg5 expression contributes to the onset of B-cell leukemia [28], Eg5 over-expression has been reported in solid tumors such as lung cancer [29], renal cell carcinoma [30], metastatic castrate-resistant prostate cancer (mCRPC) [31], non-muscle invasive bladder urothelial carcinoma [32], laryngeal squamous cell carcinoma [33], high grade astrocytic neoplasm [34]; in addition, five human pancreatic cancer cell lines [35] and Estrogen Receptor (ER)-positive human breast cancer MCF-7 cell line were also observed higher Eg5 expression [36]. Eg5 overexpression is linked to unfavorable prognosis [37]. Eg5 has been reported to contribute to cancer cell migration, and angiogenesis impairment [26]. However, it is unclear if Eg5 overexpression reflects higher proliferation rate of a cell population or true protein excess in the cell population. Furthermore, in interphase cells, the intracellular localization of Eg5 was identified as a prognostic factor in hormone-naive prostate cancer patients; patients whose tumor expressed nuclear Eg5 had a decreased median overall survival and progressed more rapidly to metastatic castrate-resistant prostate cancer [31].

The cumulative data on Eg5 motor protein described above suggest that due to its important role in spindle formation during cell division, inhibition of Eg5 could indeed have both an anti-proliferative effect as well as an anti-angiogenesis effect. Together with the fact of the low expression of the protein in neurons, using inhibitors of Eg5 in the clinic could have the potential to overcome side-effects associated with classical microtubule targeting agents such as taxol, which include neutropenia, hair loss and peripheral neuropathy [38] and can overcome taxol resistance [39].

This perspectives article focuses on small-molecule inhibitors that target Eg5, and their performance in clinical applications in cancer. Current and future challenges facing the Eg5 inhibition field are also discussed.

### 1.3 Methods for identifying novel Eg5 inhibitors (phenotype, enzymatic and silicon based HTS methods)

In a high throughput screening (HTS) assays, cell cycle arrest in mitosis is an easily detectable phenotype. A combination of use of a dot blotting with mitotic specific markers, like nucleophosmin, combined with indirect immunofluorescence microscopy using antibodies to spindle proteins, such as tubulin, to evaluate the state of spindle microtubules (Fig 1B) can be used. Indeed, one of the first successful identification of a small molecule by HTS was the identification of a compound that blocked cells in mitosis with the characteristic mono astral spindle phenotype, named monastrol [18]. The discovery of monastrol raised the possibility that Eg5 may be a clinically important mitotic target and therefore a number of chemically distinct small molecules (dihydropyridines, S-Trityl-L-cysteine,  $\beta$ -carboline and carbazoles, quanzoles, thiazoles, biphenyls and others reviewed in [40]) and their derivatives were further identified as potential antineoplastic agents with potential cancer chemotherapeutic properties (Fig 2).

One of the disadvantages of the phenotype screening assay is the subsequent work required to identify the intracellular target of the identified inhibitory small molecules. In the case of monastrol the resulting accumulation of mitotic cells with a striking monoastral spindles phenotype led the investigators to note the similarity of the mono asters in cells expressing a temperature sensitive allele of kinesin BimC in *Aspergillus nidulans* [41] as well as after microinjection of antibodies in cells [5]. Quickly after that, it became evident that monastrol could interfere *in vitro* with the ability of Eg5 to move microtubules. Loss of the Eg5 driven microtubule motility by monastrol was further attributed by the ability of monastrol to allosterically inhibit the microtubule stimulated ATPase activity of Eg5 [18].

An alternative to phenotype based screening is biochemical enzymatic assays in a high throughput setting. Eg5, like all kinesins, possesses an intrinsic ATPase activity, which is stimulated in the presence of microtubules by a factor varying from several hundred up to 10,000 times [42]. A fundamental question is how ATP binding, hydrolysis, and release of hydrolysis products, which are localized events, are harnessed to obtain unidirectional motion. A cascade of allosteric conformational changes within the motor domain is instigated following microtubule binding that lead to MgATP hydrolysis that provokes stepping of the motor along microtubules.

1 This is most likely achieved through the power stroke which is associated by a large, rapid  
2 structural change in the motor following ATP hydrolysis that can be used to do mechanical  
3 work. The release of the hydrolyzed nucleotide is the rate limiting step in the motor-ATP  
4 hydrolysis reaction. MgADP release from the motor is very rapid once the motor encounters  
5 MTs. Release of the nucleotide from the motor results in the high affinity state of the motor for  
6 microtubules (apo state). Subsequent binding of ATP to the apo-motor reduces the affinity of  
7 the motor for the MTs although it still remains bound to MTs. Hydrolysis of the MgATP to  
8 MgADP and Pi and the subsequent Pi release from the motor leads to the complete release of  
9 the motor from the MTs [43]. Since the MT binding site of the motor is in site distant to the  
10 nucleotide binding site the different nucleotide states of the motor must be communicated to  
11 the MT binding site in an allosteric manner.  
12  
13  
14  
15  
16  
17  
18  
19  
20

21 Crystallography elucidated a lot of the biochemical steps associated with the ATP hydrolysis  
22 and power stroke associated with chemomechanical step of kinesins [44][45] and particularly  
23 Eg5 [46]. The motor domain of Eg5 as well as all other kinesins fits the canonical kinesin motor  
24 domain fold with an eight-stranded  $\beta$ -sheet sandwiched between three major  $\alpha$ -helices on each  
25 side (Fig 3A)[47]. Each motor domain has one molecule of  $Mg^{2+}$ ADP bound in the nucleotide-  
26 binding pocket on the rear-left side of the motor consisting of the phosphate loop (P-loop),  
27 switch-I (sw-I), and switch-II (sw-II). Binding of the motor to MTs triggers ATP hydrolysis  
28 leading to the power stroke resulting in the stepping of the motor forwards. A key mechanical  
29 amplifier for motion is the neck linker (NL), a flexible 12–18 amino acid sequence that connects  
30 each motor head to the  $\alpha$ -helical coiled-coil stalk. The neck linker undergoes a transformation  
31 from being flexible in both the ADP-bound and nucleotide-free states to being docked along the  
32 core motor domain in the ATP-bound state (Fig 3C). NL docking of the leading motor domain  
33 positions the lagging motor domain forward along the microtubule track, thereby is specifying  
34 the direction of motility. Therefore, small molecules that could bind to the motor domain of Eg5  
35 could potentially interfere with any of the steps involved in the motor activity.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

50 These characteristic enzymatic and structural features were exploited over the years to isolate  
51 and characterize molecule inhibitors of Eg5 activity [48][49]. The resulting plethora of small  
52 molecule inhibitors of Eg5 along with the elucidation of their corresponding Eg5-ligand crystal  
53 structures led also to the virtual screening for the identification of novel Eg5 inhibitors (Fig 4  
54 and 5).  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



## 2. Enzymatic and structural characterization of Eg5 inhibitors

Over the last 20 years a number of inhibitors with different chemical scaffolds have been identified either by phenotype or enzymatic motor ATPase based HTS assays (Fig 2). Most of the molecules identified bind to the motor domain of Eg5 in stoichiometric manner inhibiting its microtubule activated ATPase activity and the Eg5 based microtubule motility *in vitro* assays and by doing so induce monoastral spindles in cells. Further chemical optimization of the initial leads has led some of the identified small molecules to clinical trials.

### 2.1 Loop 5 binding allosteric inhibitors

One group of inhibitors target a specific allosteric site in the Eg5 motor domain composed of helix  $\alpha 2$ /loop L5 and helix  $\alpha 3$ , which is approximately 10 Å away from the ATP binding site (Fig 3 and 4). This is the case for the inhibitors such as monastrol [50] and its chemical analogues S-enastron, S-dimethylenastron [51] and Mon97 [52], as well as MK-0731 [53], S-Trityl-L-cysteine (STLC) [54], Ispinesib [55], SB743921 [56], K858 [57][58] and Arry-520 [59]. Binding to this pocket induces a rearrangement of loop L5 from an “open” to a “closed” state, which allosterically transmits conformational changes in the ATP binding pocket, slowing down ADP release (Fig 3A and B). As a result, Eg5 is trapped in an “ATP-like” conformation and the mechanochemical cycle of the motor is inhibited. Based on structural information of Eg5 bound to STLC, ispinesib and Arry-520 one common theme has emerged is that ligand binding induces major structural changes in the switch II cluster (helix  $\alpha 4$ /loop L12 and helix  $\alpha 5$  region) and the so-called neck-linker region. The binding of the ligands to the loop L5 region induces conformational changes in and around the inhibitor-binding pocket (switch I), which are transmitted to the switch II cluster and the neck-linker region following helix  $\alpha 6$ . Both intermediate and final bound states for the three inhibitors were evident by their corresponding structures (Fig 3C). In the intermediate bound state, the switch II cluster is in the obstructive conformation forcing the neck linker region to be perpendicular to the motor domain whereas in the “final” inhibitor bound state the neck-linker swings about 32 Å and is trapped in the docked conformation to the motor domain [59].

### 2.2 Eg5 ATP binding competitive inhibitors

More recently, another group of Eg5 inhibitors has been found to bind to a different allosteric pocket of the Eg5 motor domain [60][61][62]. Structural analysis for three inhibitors bound to the Eg5 motor domain has been elucidated either in complex with microtubules by cryo-

1 electron microscopy in the case of GSK1 [63] or bound to the motor domain in the case of  
2 PVZB1194 [64] and BI8 [62]. GSK-1 and PVZB1194 bind at the junction of helix- $\alpha$ 4 and - $\alpha$ 6  
3 pocket which is 15 Å from the ATP-binding pocket (Fig 5) which differs from conventional  
4 allosteric inhibitors that bind to the allosteric  $\alpha$ 2/L5/ $\alpha$ 3 pocket of Eg5, mentioned in the  
5 previous section. In the presence of either inhibitor the ATP binding site was empty of either  
6 ATP or ADP consistent with biochemical assays showing the both inhibitors act as competitive  
7 inhibitors by binding to the  $\alpha$ 4 and  $\alpha$ 6 pocket near but not in the ATP binding site. The neck  
8 linker in both structures are in the docked conformation. In contrast to the loop5 L5 binding  
9 inhibitors, both GSK-1 and PVZB1194 specifically inhibit MT-bound Eg5.  
10  
11  
12  
13  
14  
15

16  
17 Another ATP competitive inhibitor of Eg5 is BRD9876 [65]. BRD9876 also only inhibits  
18 microtubule-bound Eg5. Based on similar biochemical Eg5 inhibition properties and from  
19 docking simulations BRD9876 is predicted to bind to the same helix- $\alpha$ 4 and - $\alpha$ 6 pocket as GSK-  
20 1 and PVZB1194 do.  
21  
22  
23  
24  
25

## 26 **2.3 Natural products**

27  
28  
29

30 Natural products are a rich source of bioactive compounds with a broad spectrum of biological  
31 activities. A number of them have been identified as inhibitors of Eg5 (listed in Fig 2).  
32 Terpendole E is a fungal-derived Eg5 inhibitor, which was originally identified as an acyl-CoA:  
33 cholesterol acyltransferase inhibitor. Terpendole E inhibits Eg5 ATPase activity the Eg5 driven  
34 gliding of MTs *in vitro* and cells exposed to Terpendole E block in mitosis with the characteristic  
35 mono astral spindles [66]. Interestingly, studies combining hydrogen exchange mass  
36 spectrometry with molecular dynamics of Eg5 motor domain in the presence of Terpendole E,  
37 showed that the inhibitor binds to the loop L5, as many of the allosteric Eg5 inhibitors do, but  
38 it appear to have a unique mechanism [67]. Terpendole E upon binding to the loop L5 it  
39 mediates allosteric changes that destabilize the  $\beta$  sheet core of the motor instead of inducing  
40 changes in the switch II region of Eg5 ATP binding site. The difference in the inhibition  
41 mechanism of Terpendole E may explain also the observation that Terpendole E is active in  
42 cells that are resistant to STLC or to GSK-1 inhibitors [68].  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55

56 The marine sponge extract Adociasulfate-2 (AS-2) disrupts the ATPase activity of Eg5 and  
57 inhibits the activity of kinesin 1 in MT gliding motility assay [69]. However, AS-2 is a nonspecific  
58  
59  
60  
61  
62  
63  
64  
65

1 kinesin inhibitor as it competes for microtubule binding, targeting several superfamily  
2 members including KHC, MPP1, MKLP1, RabK6, KIFC1, KIFC3, CENP-E, and Eg5 [70][71].  
3

4 Gossypol is a component of cotton seed extracts and is used as a fertility control agent due to  
5 its toxicity to sperm. Gossypol was also identified as an inhibitor of Eg5 ATPase activity [48].  
6 Gossypol has been shown to possess anticancer effects against several cancer cell lines,  
7 including HCC cells [72]. In fact, Gossypol is now in phase II/III clinical trials for various cancers  
8 (www.clinicaltrials.gov). However, Eg5 inhibition may not be its primary intracellular target  
9 since numerous studies have revealed that Gossypol and its derivatives target the Bcl-2 family  
10 of proteins containing the anti-apoptosis proteins Bcl-2 and Bcl-XL [73].  
11  
12  
13  
14  
15  
16  
17  
18

19 Curcumin, a polyphenol derived from the rhizome of the plant Curcuma has been used  
20 traditionally in traditional systems of medicine because it induces toxicity selectively in tumor  
21 cells. The anti-proliferative mechanisms attributed to curcumin involve multiple signaling  
22 pathways and cellular targets including several enzymes, growth factors, transcription factors,  
23 cytokines, apoptotic regulators, DNA synthesis, and proteins involved in cell division and cell  
24 cycle regulation, including Eg5 [74]. Competition experiments for Eg5 binding in the presence  
25 of monastrol indicated that curcumin binds to a site different from monastrol in a  
26 stoichiometric manner [75]. Circular dichroism coupled to molecular dynamics indicated that  
27 curcumin could bind to a novel druggable site located 44 Å away from the microtubule binding  
28 site on Eg5, 34 Å away from ATP binding site and 28 Å away from the monastrol binding site.  
29 Curcumin in contrast with the L5 loop binding inhibitors stabilized the interactions between  
30 Eg5 and microtubules at higher concentrations. The most important conformational change  
31 observed with Eg5 was the opening and closing of switch II loop flanking the active site of Eg5.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

## 45 **2.4 Depletion of Eg5 expression in targeted cells.**

46  
47  
48

49 RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a  
50 wide range of debilitating diseases with high unmet medical need and to date, up to ten  
51 oligonucleotide drugs have received regulatory approval from the FDA [76]. The potential to  
52 selectively inhibit Eg5 overexpressing tumors using RNAi-nanomedicines may be a highly  
53 promising strategy to halt tumor progression and improve overall patient survival. Indeed, in a  
54 HTS screening of a library of 2'-methoxyethyl-modified antisense oligonucleotide (2'MOE ASO)  
55 molecules, one of the most effective ASO identified was that targeting Eg5 [77]. Similarly, a  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 number of siRNAs as well as shRNAs were shown effective in disrupting Eg5 expression in cells  
2 leading to monoastrol spindles and mitotic arrest. However, efficient tissue-specific delivery of  
3 siRNA remains the major limitation in the development of RNAi-based cancer therapeutics [76].  
4 ALN-VSP was the first systemically delivered RNAi therapeutic which included two siRNAs  
5 enclosed in lipid nanoparticles of 80-100 nm in diameter, intended to target two genes critical  
6 for the growth and development of cancer cells: vascular endothelial growth factor (VEGF) and  
7 Eg5 [78]. An alternative approach to silence Eg5 expression was recently achieved using  
8 PEGylated DC-Chol/DOPE cationic liposomes, containing Eg5 shRNA-expressing  
9 plasmid/liposome lipoplexes that induced the long-term Eg5 silencing in the tumor sites of  
10 tumor-bearing mice leading to more sustained anticancer effects [79].  
11  
12  
13  
14  
15  
16  
17  
18

### 19 **3. Status of past and ongoing clinical trials with anti-Eg5 strategies.**

#### 22 **3.1 The basic idea of inhibiting Eg5 as an anti-mitotic agent**

23  
24  
25  
26 Since the discovery of monastrol as mitotic inhibitor, and the demonstration that it targets  
27 specifically Eg5 and not microtubules, targeting Eg5 was validated as a proof of concept that it  
28 is possible to develop novel anti-mitotic inhibitors, other than microtubule targeting agents, in  
29 order to block tumor cell proliferation growth. The purpose of this perspective is not to discuss  
30 how anti-mitotic agents kill cells in mitosis or after aberrant mitotic exit. Readers can find  
31 excellent reviews on how antimitotic agents kill cells in related reviews [80][81][82]. However,  
32 it is widely accepted that the ability of anti-mitotic agents to suppress tumor cell proliferation  
33 lies in their capacity to trigger cell death, induced either in mitosis during a prolonged mitotic  
34 arrest, or post mitotically following a premature exit from mitosis [81]. Nonetheless though, it  
35 is worth mentioning that using single-cell assays it has been shown that the response of several  
36 cancer cell lines to anti-mitotic drug treatment varied widely between cell lines [83]. In some  
37 cases the sensitivity of the cells to anti-mitotic drugs correlated with the loss of the expression  
38 of X-linked inhibitor of apoptosis (XIAP) during the drug response [84]. Similar variation in  
39 response to Eg5 inhibitors of different cell lines was noticed and interestingly, Eg5 inhibition  
40 induced greater cell death in cancer cell lines than in nontransformed cells [85].  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55

56 Cancer chemotherapeutic strategies based on microtubule targeting agents, such as taxol  
57 chemotherapy, are associated with severe side effects, such as neurotoxicity,  
58 myelosuppression, fatigue and others [86][38], since microtubule functions are ubiquitously  
59  
60  
61  
62  
63  
64  
65

needed in all cells, healthy and tumor cells, during all phases of the cell cycle. As mentioned earlier Eg5 is minimally expressed in adult tissues and therefore is expected to have minimal neurotoxic side effects. Furthermore, the emergence of taxol resistance [87] in treated tumors raised also the need for new anti-mitotic agents such as those targeting Eg5 as substitutes to taxol treatment [39]. Therefore, a lot of pharmaceutical and biotechnology companies developed Eg5 inhibitors and a certain of them entered clinical trials as anti-neoplastic agents against a variety tumors (Table I).

### 3.2 Results of the clinical trials

All of the identified Eg5 inhibitors in addition to their ability to inhibit the enzymatic activity of the motor protein in *in vitro assays*, were efficient in inhibiting tumor cell lines in mitosis and stopping tumor cell proliferation in mouse tumor cells in xenograft models. However, many of the tested inhibitors had limited success in clinical trials. In summary, the results for the various phase I trials were encouraging in that the drugs at their maximal tolerated dose (Table I) were well tolerated with the most common side-effects observed were suppression of neutrophil production (neutropenia), anemia and in some cases liver toxicity. Most importantly, and unlike the microtubule inhibitors, such as taxanes and vinca alkaloids, neurotoxicity was not observed, as it was initially expected.

More specifically, in the case of ispinesib (or SB-715992) partial responses were observed in less than 10% of the cases although stable disease was noted in 55% of patients with renal carcinoma [88]. Two studies with ispinesib focused particularly on mCRPC patients, gave ambiguous results. In a phase I study, six out of fourteen mCRPC patients had stable disease for  $\geq 18$  weeks and one patient had a prostate-specific antigen (PSA)-decrease of  $>50\%$  when ispinesib was combined with docetaxel [89]. However, in a phase II study in which ispinesib was administered as monotherapy, no responses were reported [90]. Twenty out of 21 patients had been treated with docetaxel prior to ispinesib. Immunohistochemistry analysis on archival tumor tissue from sixteen patients indicated that only one tumor stained positive for Eg5. It was concluded that ispinesib is not effective in primary prostate cancer (PCa) due to their low mitotic index, resulting in low Eg5 expression. Similarly, no conclusive evidence of benefit was seen with HCC [91], melanoma and head and neck squamous cell carcinoma [92][93].

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

In a multicenter phase I/II study of SB-743921 [94] with patients with relapsed or refractory lymphoma it was shown that the dose limiting toxicity and the maximum tolerated dose can be markedly increased if the drug is administered together with granulocyte-colony stimulating factor [95]. Out of 56 patients, one patient was drug resistant, four of 55 patients experienced a partial response (three in Hodgkin lymphoma and one in non-Hodgkin lymphoma); 19 patients experienced stable disease and 33 patients developed progression of disease. The results demonstrated that combination regimens in addition to Eg5 inhibitors may have a positive complementary role.

In patients with either urothelial cancer or refractory acute myeloid leukemia AZD-4877 [96] demonstrated no complete or partial responses [97][98][99]. Patients with solid tumors exposed to ARQ-621 [100] only 6/48 patients experienced disease stabilization for >4 months [101] whereas those exposed to MK-0731 [53] exhibited no complete or partial responses [102]. Phase I and II clinical trials with LY 2523355 ([103]; clinical name litrinosib) in one hundred and seventeen patients showed that the therapeutic index for this drug class is narrow; only 2% of the patients achieved partial response, and 20% maintained stable disease for  $\geq 6$  cycles [104][105].

ALN-VSP is designed to target the expression of Eg5 and the vascular endothelial growth factor, or VEGF, required for tumor growth by specific siRNAs [78]. In the trial, the patients were treated at doses ranging from 0.1 to 1.5 mg/kg. The results of ALN-VSP Phase I trial demonstrated safety and tolerability of multiple doses of ALN-VSP. ALN-VSP as a single-agent had anti-tumor activity, and showed RNAi-mediated target mRNA cleavage in both hepatic and extra-hepatic tumors. Both siRNAs in ALN-VSP were detected in liver tumor biopsies and in metastases involving the adrenal gland, lymph nodes, and abdominal cavity, across multiple different tumor types. Strikingly it was noted that the ALN-VSP phase I trial included a complete response in a patient with nodal and extensive liver metastases, as well as prolonged disease stabilization for as long as 1 to 1.5 years in patients with hepatic and extrahepatic metastases. Disease control was achieved in one of 13 patients (8%) treated at doses less than or equal to 0.4 mg/kg versus 12 of 24 (50%) treated at doses greater than or equal to 0.7 mg/kg, including seven of 11 (64%) treated at the proposed Phase II dose of 1.0 mg/kg. However, further clinical studies on ALN-VSP are on hold, most likely due to the legal disputes between the two companies involved, Alnylam and Tekmira Pharmaceuticals, regarding the intellectual property of lipid nanoparticle delivery technology.

1 Within this avalanche of negative results though, Arry-520 [106] (clinical name filanesib)  
2 turned out to be a promising agent for the treatment of patients diagnosed with refractory  
3 and/or relapsed multiple myeloma [107]. For a more detailed account of the results obtained  
4 following clinical trials with Arry-520 one can read the recent review by Algarin et al [108].  
5 Briefly, Arry-520 as single agent achieved only partial response in 1 out of 34 patients suffering  
6 from AML and no significant clinical responses were observed with patients with solid tumors  
7 treated with Arry-520. However, Arry-520 as single agent showed an overall response rate of  
8 16% and 15% when low dose the anti-inflammatory dexamethasone was added in heavily  
9 pretreated multiple myeloma patients [109]. The overall survival of 19 months were obtained  
10 with Arry-520 as mono therapy and 10,7 months in combination with dexamethasone. These  
11 encouraging results prompted the exploration of potential combinations with proteasome  
12 inhibitors such as bortezomib [110] and carfilzomib [111][112] in combination with or without  
13 dexamethasone. Combining Arry-520 with the proteasome inhibitor bortezomib produced  
14 response rates as high as 42 %. Combination of Arry-520 with the proteasome inhibitor  
15 carfilzomib gave response rates as high as 37 %, with 5 % of patients achieving a near complete  
16 response and 32 % a partial response. Furthermore, the efficacy of Arry-520 in clinical trials  
17 was associated with the expression levels of  $\alpha$ -1 acidic glycoprotein (AAG); low levels of AAG in  
18 the serum of patients were correlated with a better chemotherapeutic index compared to  
19 higher AAG levels [113]. Therefore, the levels of AAG in the serum can be used as a useful  
20 predictive biomarker to identify patients that will be responsive to Arry-520 treatment. A more  
21 targeted selection of patients based on the level of AAG may increase the Arry-520 response  
22 rates possibly making Arry-520 based therapy to be equally effective as the recently developed  
23 anti-myeloma immunotherapy based on monoclonal antibodies [114]. Based on these  
24 encouraging results Arry-520 is scheduled to enter Phase III clinical trials for multiple  
25 myeloma.

### 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 **3.3 Possible reasons for the failure**

#### 50 51 52 **3.3.1 Pharmacokinetics and the proliferation rate paradox**

53  
54  
55  
56 The obvious question arising from the above described clinical trials is why Arry-520 was  
57 relatively successful compared to the rest of the compounds tested. The low therapeutic index  
58 of the tested Eg5 inhibitors, such ispinesib, SB-743921, AZD-4877, and MK-0731 is not due to  
59  
60  
61  
62  
63  
64  
65

1 lack of target engagement since the inhibitors target normal cell proliferation leading to  
2 neutropenia. However, taking into account the pharmacokinetic data derived from the phase I  
3 clinical trials of the compounds tested, one determining factor of success might be the  
4 elimination half-life of each compound [115]. As shown in Table 1, the elimination half-lives of  
5 ispinesib, SB-743921, AZD-4877, and MK-0731 are all <30 h, whereas the corresponding half-  
6 life of ARRY-520 was found to be >90 h. Therefore, the longer half-life of Arry-520 compared to  
7 other Eg5 may be one of the reason for the better therapeutic index of Arry-520.  
8  
9

10  
11  
12  
13 In addition to the long elimination half-life of the inhibitor, another determinant factor for the  
14 efficacy of a given treatment may be depended also on how often the cells in a given tumor type  
15 divide. A given mitotic inhibitor to act in mitosis needs to be present when the cells reach cell  
16 division. Most of the inhibitors are administered to the patients in intermittent fashion and not  
17 in continuous dosing. However, approximately only 1% of the tumor cells solid tumors are in  
18 mitosis at any given time [116], a phenomenon referred to as the ‘proliferation rate paradox’  
19 [117]. Therefore, any given mitotic inhibitor needs to be present long enough into the serum  
20 of patients in order to be effective in mitotic cells of the slowly dividing tumors. This means that  
21 for an anti-mitotic agent to be effective *in vivo*, it must remain in contact with the tumor for  
22 considerably longer than the average cell cycle time—a criterion that Arry-520 appears to  
23 satisfy. The longer half-life of Arry-520 compared to other Eg5 inhibitors combined with the  
24 high proliferation rate of relapsed multiple myeloma cells (14% to 83%) may be two key factors  
25 to explain the better therapeutic index of Arry-520. In support of this argument may be the  
26 observed clinical data using the oral Eg5 inhibitor 4SC-205 indicating that a continuous dosing  
27 scheme of 20 mg per patient, once daily could overcome this ‘proliferation rate paradox’. A  
28 clinical response (stable disease) was observed in 67% of patients for more than 100 days  
29 undergoing this regimen [118].  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

### 46 **3.3.2 Acquired resistance to Eg5 inhibitors**

47  
48  
49  
50  
51 Another explanation for the lack of efficacy of the Eg5 inhibitors in the clinic may due to the  
52 characteristic genetic instability of tumors [119]; there might be tumor cells carrying, for  
53 example, preexisting mutations within the L5 loop ligand binding site, rendering thus Eg5  
54 resistant to inhibition. To date though, there are no clinical relevant mutations in Eg5 reported  
55 that might be involved in resistance to any anti-Eg5 inhibitor. What has been shown though  
56 after clonal selection of cells in the presence of Eg5 inhibitors such as ispinesib [94][120], and  
57  
58  
59  
60  
61  
62  
63  
64  
65



BRD9647 [65], is resistant cells that express mutant Eg5 having amino acid substitutions in the inhibitor binding pockets. For example, the mutation D130V which is in the helix  $\alpha$ 2/loop L5/helix  $\alpha$ 3 allosteric binding site is associated with ispinesib resistance and the mutation Y104C, located in the distinct Eg5 allosteric binding site between the  $\alpha$ 4 and  $\alpha$ 6 helices is associated with BRD9647 resistance. Clonal selection of cells exposed to STLC also resulted to the identification of single point mutations on the *Kif11* gene that are associated with resistance [121][122].

As mentioned previously the most notable conformational change observed upon binding of the Loop L5 inhibitors is the adoption of a “closed” conformation of loop L5. This is in contrast with the “open” conformation observed in the absence of an allosteric ligand. However, the transition from the “open” to “closed” conformation of loop L5 is taking place also in normal motor function [123]. Interestingly the SB743921 Eg5 inhibitor was identified following a screen using the two ispinesib resistant cell line clones expressing either the Eg5(D130V) or Eg5(A133D) alleles [94]. Strikingly, the crystal structures of the WT Eg5 and Eg5(A133D) bound to SB743921 turned out to be very similar [56]. However, extended molecular dynamics simulations revealed that when the WT motor is bound to the inhibitor, Ala133 along with the neighboring Pro137 residue are able to transmit a perturbation pathway through the protein to the nucleotide site resulting to inhibition. In contrast, in the Eg5(A133D)-SB743921 complex, there are local rearrangement of hydrogen bonding and salt bridging that transmit structural changes throughout the whole complex that would block the inhibitor induced allosteric transmission to the nucleotide site rendering thus, the motor resistant to the inhibition [56].

Furthermore, Infrared spectroscopy was used to provide a direct measure of the mechanochemical coupling between the loop L5 and the  $\beta$ -sheet central core of the Eg5 motor domain in a panel of single point mutations with different amino acid substitutions. The data showed that amino acid substitutions at positions E116 and E118 at the N-terminus of the Loop L5 resulted in changes in the secondary structure of Eg5 in solution irrespective of mutation or inhibitor binding [124]. The results pointed that mutations that may induce loss of Loop L5 rigidity may lead to reduced inhibitor sensitivity and that not all the Loop L5 binding have the same inhibitory effects on Eg5 activity. Furthermore, by infrared spectroscopy was possible to show that the secondary structure changes of the Eg5 motor domain bound to monastrol are different than those coupled to the more potent inhibitor STLC, suggesting thus that the impact of binding of different Eg5 Loop L5 inhibitors may be not the same.

1 Nonetheless, extensive mutagenesis analysis in the helix  $\alpha 2$ /loop L5/helix  $\alpha 3$  allosteric binding  
2 site of Eg5 has been shown to confer resistance to a variety of other loop L5 inhibitors (Table II  
3 Fig 3D), including monastrol, STLC, ispinesib and others [125][126][127][128]. Notably,  
4 mutations to specific residues in the inhibitor-binding pocket (including D130A; D130V; D133A  
5 and L214A), although they do not alter appreciably the binding of monastrol or STLC to the  
6 motor domain [126], can overcome inhibition by blocking the allosteric communication  
7 network to the ATP binding site [56].  
8  
9  
10  
11  
12  
13  
14

15 When Arry-520 was assessed in two cell lines selected for the expression of either Eg5(D130A)  
16 or Eg5(L214A) STLC-resistant alleles, mutations previously shown to convey resistance to loop  
17 L class of inhibitors [129], it was inactive in both [59]. However, when the cells were challenged  
18 with ispinesib, the Eg5(D130A) expressing cells were resistant, but those expressing  
19 Eg5(L214A) were strikingly sensitive. Molecular dynamics simulations suggested that subtle  
20 differences in ligand binding and ligand flexibility may alter allosteric transmission from the  
21 loop L5 site that do not necessarily result in reduced inhibitory activity in mutated Eg5  
22 structures [59]. Even though the data predict that cells challenged with Arry-520 in the clinical  
23 setting are likely to acquire resistance through point mutations in the Eg5 binding site, the data  
24 for ispinesib suggest that this resistance mechanism is not scaffold independent as previously  
25 thought [130], and new inhibitors can be designed that retain inhibitory activity in these  
26 resistant cells.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

### 40 **3.3.3 Functional plasticity of mitotic kinesins substituting for loss of Eg5 function**

41  
42  
43 Although Eg5 plays a central role in spindle formation by contributing the necessary forces for  
44 centrosome separation [17], in cells there exist redundant pathways that can achieve  
45 centrosome separation leading to spindle bipolarity. As mentioned in the introduction Eg5 is  
46 one of the 45 members of the kinesin superfamily of motor proteins from which more than 15  
47 are implicated in mitosis [2]. One of such mitotic motors, Kif15 (member of the *kif12* subfamily  
48 of kinesins), can fully reconstitute bipolar spindle assembly in cells in the absence of Eg5  
49 activity [131][58]. Kif15 is not essential for spindle assembly but when ectopically  
50 overexpressed in cells, the over expressed Kif15 together with TPX2, a microtubule binding  
51 protein reported to be also a binding partner of Eg5, can crosslink and slide two antiparallel  
52 microtubules apart, thereby driving centrosome separation [132].  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 Studies aiming to understand how cells can adapt to the lack of Eg5 activity demonstrated that  
2 resistance to STLC Eg5 inhibitor was associated with the expression of rigor mutant of Eg5,  
3 G268V [122]. G268 is located into the switch II nucleotide binding area and the G268V traps the  
4 motor in a microtubule binding state leading to a strong microtubule crosslinking. Eg5 is  
5 converted in these cells from a motile force generator to a static MT crosslinker. Kif15 is  
6 normally restricted to kinetochore-MTs because of its preferential binding to MT bundles.  
7 Therefore, due to the Eg5(G268V) induced cross linking Kif15 changes its distribution and is  
8 enriched also to the rest of spindle microtubules contributing so in the formation of normal  
9 bipolar spindle. It is worth noting also that the Kif15-Eg5(G268V) resistance was not associated  
10 to Kif15 overexpression but solely in changes in Kif15 localization to the whole spindle instead  
11 to only kinetochore microtubule bundles. This observation strongly suggests that a  
12 combination of Eg5 inhibitors and Kif15 inhibitors may be an effective anti-proliferative  
13 chemotherapeutic regimen for targeting rapidly dividing cancer types. Although the  
14 development of Kif15 inhibitors is in its infancy, GW108X [133], an oxindole compound as well  
15 as KIF15-IN-1 [134] and benserazide [135] may serve as leads to further develop Kif15  
16 inhibitors into clinically relevant agents. Moreover, in a SB743921-resistant cell model that  
17 depends on Kif15 activity it was shown that inhibition of the centrosome associated AURKA  
18 kinase could be an effective option to overcome resistance to Eg5 inhibitors [136].  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

36 Resistance to STLC in HeLa cells was also attributed to the prophase centrosome separation  
37 pathway, which depends on nuclear envelope-associated dynein, a minus end microtubule  
38 directed motor protein [137]. While Eg5 acts on centrosome pairs, dynein pulls on individual  
39 centrosomes, and in combination with the activity of Kif15 can drive centrosome separation  
40 and establishment of bipolar spindle. In naive cells both Eg5 and nuclear envelope-associated  
41 dynein centrosome separation pathways are operating.  
42  
43  
44  
45  
46  
47  
48

49 One additional aspect regarding the response of the cells to Eg5 inhibitors may also be related  
50 to the premature centrosome separation which appears to be related to the epidermal growth  
51 factor receptor signaling (EGFR) pathway. Different cancer cell lines upon stimulation of the  
52 EGFR signaling pathway by EGF induce premature centrosome separation in S phase [138]. A  
53 direct consequence of this is that cells with high EGFR levels fail to arrest in mitosis upon Eg5  
54 inhibition, by STLC for example. Therefore, a combinatorial targeting of EGFR and Eg5 may be  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 a more effective chemotherapy approach for the types of tumors that are rich in EGFR and not  
2 responsive to Eg5 inhibition.  
3

4 Centrosome separation during the G2/M transition is tightly regulated not only by cell cycle  
5 signaling pathways that favor separation, as mentioned above, but also by pathways that inhibit  
6 premature separation. In prophase, p21-activated kinases (Pak1 and Pak2) counteract  
7 centrosome separation by a Cdk1 dependent phosphorylation of their activator Tiam1.  
8 Interestingly, depletion of Pak1/2 allows cells to escape monopolar arrest by Eg5 inhibition by  
9 monastrol, highlighting the potential importance of this signaling pathway in the development  
10 of an additional pathway that could lead to resistance to Eg5 inhibitors [139].  
11  
12  
13  
14  
15  
16  
17  
18

## 19 **4. Future directions**

### 20 **4.1 Towards single-target selectivity Antibody-drug conjugates**

21  
22 The field of Antibody-Drug Conjugates (ADCs) poses a promising therapeutic option for  
23 malignant patients. ADCs are developed for targeted delivery of cytotoxic payloads to tumor  
24 cells. ADCs share a common design of antibody, linker, and cytotoxic payload [140]. At present,  
25 four ADCs are in clinical use approved by the FDA and European Union (EU) for treating  
26 different kinds of cancer; two are conjugated to DNA damaging agents and two to MT disrupting  
27 agents. More than 60 ADCs are at different clinical stages and their results have sparked  
28 significant interest in the rapidly growing number of ADC candidates. Recently, antibody  
29 prodrug conjugates (APDCs) with Eg5 inhibitor payloads represent a versatile novel approach  
30 for cancer treatment [141]. A novel pyrrole subclass of Eg5 inhibitor (KSOi SMOL; Fig 2) was  
31 linked with a stable peptide linker to tumor recognizing antibodies such as BAY-865 targeting  
32 the receptor of TWEAK (tumor necrosis factor [TNF]-like weak inducer of apoptosis) [142]. The  
33 peptide linker is a substrate for the Legumain, a lysosomal endopeptidase with optimal activity  
34 at an acidic pH of ~4-5 that shows an increased expression and thus higher activity in solid  
35 tumors compared to most healthy tissues. In preclinical studies, the Eg5-ADCs targeting  
36 TWEAKR demonstrated potent and selective anti proliferative activity in a panel of TWEAKR-  
37 positive cancer cell lines in vitro and high antitumor efficacy in patient-derived xenograft  
38 models.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57

58 More recently BAY-943, a novel ADC consisting of a humanized internalizing anti-IL3RA IgG1  
59 antibody conjugated via lysine residues to the Eg5 motor protein inhibitor was conceived to be  
60  
61  
62  
63  
64  
65

1 tested in IL3RA-positive tumor cells [143]. IL3RA expression is restricted to myeloid progenitor  
2 cells, plasmacytoid dendritic cells (pDCs), basophils and - at low levels - monocytes and B-  
3 lymphocyte subsets. BAY-943 showed efficacy in IL3RA-positive AML and HL models and had  
4 a favorable safety profile in monkey repeat dose studies. Thus, ADCs with Eg5 inhibitors as  
5 payload offer a promising new approach for tumor treatment.  
6  
7  
8

## 9 **4.2 Virtual screening**

10  
11  
12 Virtual screening strategy is widely applied for identification of novel targeted drugs. This  
13 strategy is generally divided into structure based virtual screening and ligand based virtual  
14 screening. The increasing number of solved X-ray crystal structures in the PDB of Eg5 bound to  
15 structurally diverse inhibitors (Fig 4 and 5) allowed by the combination of pharmacophore  
16 modeling and molecular docking the identification of three novel Eg5 inhibitors bearing  
17 quinazoline and thioxoimidazolidine scaffolds [144]. In an another virtual screening study  
18 based on shape similarity to STLC, molecular docking and phenotype screening allowed the  
19 identification of a novel inhibitor, YL001 having a 1,5-disubstituted tetrazole scaffold [145].  
20 YL001 inhibits the ATPase activity of the motor, blocks cells in mitosis and reduced melanoma  
21 tumor growth by 60% and significantly prolongs median survival time by more than 50% in a  
22 xenograft mouse model. A limitation of the virtual screening strategy is that although it may  
23 lead to the identification of small molecules that fulfill all the features of a pharmacophore,  
24 resembling those of known inhibitors, they may not display similar inhibitory activities in  
25 enzymatic and cell based assays [146]. To date, none of the identified Eg5 inhibitors by virtual  
26 screening have entered clinical trials yet. However, since virtual screening methods are  
27 relatively economic and efficient in identifying new lead compounds and based on the fact there  
28 are over  $10^{63}$  drug-like molecules [147], virtual screening combined with virtual library of  
29 compounds may lead to novel Eg5 inhibitors in the future.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

## 48 **4.3 Eg5 as a target for neuronal repair**

49  
50  
51  
52 Based on the role of Eg5 in mitosis in the crosslinking and gliding of anti-parallel microtubules,  
53 Eg5 seemed like a good candidate motor to drive microtubule sliding in neurons. Studies on  
54 rodents have shown that mouse neurons, in contrast to other somatic cells, express a homolog  
55 of Eg5 well past their terminal mitotic division [9]. Eg5 in neurons is thought to normally  
56 generate forces that oppose axonal growth, presumably by partially suppressing the forward  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 advance of microtubules of axons [10]. Eg5 is localized in discrete and functionally important  
2 regions of developing neuronal processes and Eg5 plays an essential role in polarizing the MT  
3 array in response to cues that cause the growth cone to turn since RNAi knockdown of Eg5  
4 results in a more branched axon [148]. The role of Eg5 in regulating the length of axons and the  
5 migration of neurons in culture was linked to its phosphorylation as it was shown for its role in  
6 mitosis [149]. Furthermore, in neurons, pharmacological inhibition of Eg5 resulted in longer  
7 axons, suggesting a key role for this motor in the development of the nervous system [150][11].  
8 Theses observations raised the interesting possibility that exposure for limited windows of  
9 time of Eg5 inhibitors to injury sites could help to nerve regeneration [151].  
10  
11  
12  
13  
14  
15

#### 16 17 **4.4 Eg5 as a target in glioblastoma.** 18 19 20

21 An ideal glioblastoma (GBM) treatment needs to engage targets that drive proliferation as well  
22 as invasion, with brain penetrant therapies. A recent RNA-Seq analysis from biopsies of human  
23 glioblastomas revealed that most of the mitotic relevant kinesins including Eg5 are  
24 overexpressed [152]. Further analysis showed that expression of Kif11 (the gene coding for  
25 Eg5) is up-regulated in tumor initiating cells (TICs) compared to non-TICs, at both the RNA and  
26 protein levels. Systemic administration of ispinesib to mice bearing orthotopic, TIC-derived  
27 GBMs produced monopolar spindles phenotype, as well as a prolongation in survival, implying  
28 that sufficient amounts of drug reach the intracranial tumors to exert a therapeutic effect.  
29 However, one major obstacle in effective treatment of glioblastomas in the clinic is the diffuse  
30 nature of malignant gliomas. Data obtained by an *in vitro* Transwell assay demonstrated that  
31 TIC invasion could be abolished by ispinesib. Since Eg5 is a key player in both proliferation and  
32 motility in glioblastoma tumor cells, Eg5 is thought to be a compelling therapeutic target for  
33 glioblastoma by administering Eg5 inhibitors intracerebrally with technologies that are already  
34 being used clinically, such as convection-enhanced delivery (CED), where prolonged  
35 intracerebral CED could be achieved with a subcutaneous implantable infusion pump [152].  
36 More recent data with a mouse model of GBM showed that combining ispinesib treatment with  
37 a compound that improves its brain accumulation, such as elacridar, a P-glycoprotein (P-gp)  
38 and Breast cancer resistance protein (Bcrp), an efflux inhibitor at the blood-brain barrier, can  
39 improve significantly its efficacy [153]. Another putative inhibitor of GBM maybe the orally  
40 available Eg5 inhibitor SCH 2047069 [154] which it was shown in rats it could penetrate the  
41 blood brain barrier [155].  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 Furthermore, recent efforts in understanding the role of overexpression of 3 different kinesins,  
2 Kif11, Kif12 and Kif23 in malignant peripheral nerve sheath tumor (MPNST) cells led to the  
3 observation that MPNST cells are more sensitive to Arry-520 treatment compared to normal  
4 fibroblasts; a synergistic effect was also observed when MPNST cells were exposed to Arry-520  
5 and the BRD4 epigenetic inhibitor JQ1, especially in Kif15 depleted cells [156].  
6  
7  
8

#### 9 **4.4 Overcoming resistance**

10 The vast majority of metastatic cancers remain incurable. Treatment with standard approaches  
11 may extend survival, but ultimately fails due to the emergence of resistant cells. Resistance to  
12 targeted cancer therapy can be considered in terms of Darwinian adaptation. Due to the high  
13 levels of intra-tumor heterogeneity (ITH) [119], a huge number of cells in a tumor, due to  
14 genetic or epigenetic alterations even before treatment begins, are drug resistant. One  
15 approach to overcome single drug resistance is to follow a drug combination approach.  
16 Combining different drugs, within a narrow therapeutic window at the same time improves  
17 survival by a few months. One limiting factor in drug combination approach is the high toxicity.  
18 Nonetheless, the Eg5 inhibitor Arry-520 gave encouraging results in multiple myeloma therapy  
19 in phase II clinical trials not only as a mono therapy but also in combination with proteasome  
20 inhibitors. Similarly, the presence of elacridar —a potent non-toxic P-gp and Bcrp inhibitor—  
21 improves brain accumulation of ispinesib resulting in superior *in vivo* target engagement,  
22 reduced tumor growth and extended survival in a mouse model of glioblastoma. It may be  
23 possible also to target tumors by targeting Eg5 with different classes of Eg5 inhibitors: one  
24 targeting the helix  $\alpha 2$ /loop L5/helix  $\alpha 3$  allosteric site and the other targeting the distinct Eg5  
25 allosteric binding site between the  $\alpha 4$  and  $\alpha 6$  helices. The double hit approach will significantly  
26 limit the chances of selecting resistant clones carrying mutations that could confer resistance  
27 to both Eg5 inhibitors with distinct targeting sites.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

46 Another recently proposed method to overcome resistance is to drive by evolutionary steering  
47 to collateral drug sensitivity [157]. This approach is based on the prediction that resistance to  
48 one drug may make the resistance of cancer clone cells more sensitive to a second drug, a  
49 phenomenon known as collateral sensitivity. And indeed, in a recent proof of concept study  
50 using a non-small cell lung cancer line treated with trametinib, a MEK1/2 inhibitor, the  
51 resistant subclones were very sensitive to Eg5 inhibitors such as, ispinesib and SB-74392,  
52 among others. Therefore, there might be a new window of opportunity for already clinically  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 tested Eg5 inhibitors to be tested as second line treatment following emergence of drug  
2 resistance by targeting a different pathway.  
3

#### 4 **4.5 Kinesin-5 as a target to human pathogens**

5  
6 Based on the paradigm of Eg5 as a drug candidate for cancer therapy, kinesin-5 inhibition could  
7 have wider applications in disease control, for example in killing eukaryotic pathogens such as  
8 fungi. Indeed, screening for inhibitors of the kinesin-5 member of the pathogen *C albicans* led  
9 to the identification of an aminobenzothiazole (ABT) compound that turned out to inhibit the  
10 fungal kinesin specifically [158]. ABT was 10- to 50-fold less active against Eg5 (human),  
11 MmEg5 (mouse) and AnBimC (*A. nidulans*) motor domains. Interestingly, based on biochemical  
12 characterization of ABT revealed that the inhibitor does not belong to Loop L5 class of allosteric  
13 inhibitors but was an ATP competitive inhibitor resulting in rigor like state leading to tight  
14 association of the motor to microtubules.  
15  
16  
17  
18  
19  
20  
21  
22  
23

24 Recent structural analyses of two kinesin-5 members from two different fungi, Cut7 from  
25 *Schizosaccharomyces pombe* [159] and UmKin5 *Ustilago maydi* [160], a fungus that infects corn  
26 and causes the disease corn smut, elucidated that the overall structures of the ATP-like state of  
27 UmKin5 and Cut7 are similar to that observed for other plus-end directed kinesins, and that the  
28 core motor-microtubule interaction are tightly conserved. However, the structures also  
29 highlighted non-canonical features in these fungal motors due to divergent inserts in fungal  
30 kinesin-5 motor domains. In both fungal kinesins-5 the Loop L5 protrudes away from the motor  
31 domain in contrast to the Loop L5 of human Eg5. The identified structural differences in the  
32 Loop L5 explain why the Cut7 is not sensitive to STLC inhibition. Based on the structural  
33 analysis of the two fungal kinesins-5 as well as on divergent inserts in fungal kinesin-5 motor  
34 domains suggest that identification of specific inhibitors to fungal kinesins with a possible  
35 fungicide activity may be possible.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

48 Malaria parasites of the genus *Plasmodium*, which infect many vertebrate hosts including  
49 humans, and is transmitted by female *Anopheles* mosquitoes [161] code also for a kinesin-5  
50 motor protein. The kinesin 5, of *Plasmodium vivax* and *Plasmodium falciparum* contain Loop-  
51 5 sequences that are longer than and divergent from the human ortholog Eg5 [162]. In  
52 *Plasmodium berghei* during cell division kinesin-5 associates with the spindle microtubules and  
53 is important for efficient production of infectious sporozoites [163]. In a screen for inhibitors  
54 selective for the Kinesin-5 ATPase activity of *P.vivax* and *P. falciparum*, identified the lead  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

compound MMV666693 as an allosteric inhibitor of the motor domain of the two parasites [162]. Interestingly, MMV666693, an oxazine derivative, was a member of the “druglike” compound subset of proliferation inhibitors within the Malaria Venture validated collection known to strongly inhibit erythrocytic-stage *P. falciparum* [164]. However, the binding site of the MMV666693 to the parasite kinesin-5 is not yet known.

## 5. Concluding remarks

Eg5 has been part of a large group of mitotic targets that are undergoing intensive studies in the pursue of novel cancer therapeutics. We have come long ways since the discovery of monastrol as the first inhibitor of Eg5. The initial burst of excitement and surge of activity in identifying novel Eg5 inhibitors were followed by disappointing clinical results. Further pursue of more potent inhibitors confirmed the rule that going from a promising compound to an approved drug is still a long and uncertain process. Nonetheless, the so far characterized Eg5 inhibitors have been proven to be indispensable as chemical genetics tools for gaining biological insights in basic cell biology issues regarding the roles of Eg5 and other kinesin motors in fundamental cellular functions such as centrosome separation and spindle microtubule organization in cell division. Moreover, the knowledge accumulated from the failures in the clinic led to recent successes giving renewed hopes for the use of Eg5 inhibitors for hematological cancers. Natural product chemists, biochemists, cell and structural biologists in academia and pharmaceutical industry will continue to search for new products with unique chemical structures that may have meaningful medical applications. Having access to a greater portion of the chemical universe [147], the chances of discovering a star molecule targeting Eg5 should be greater too.

- [1] R. Le Guellec, J. Paris, A. Couturier, C. Roghi, M. Philippe, Cloning by differential screening of a *Xenopus* cDNA that encodes a kinesin-related protein, *Mol. Cell. Biol.* 11 (1991) 3395–3398. <https://doi.org/10.1128/mcb.11.6.3395>.
- [2] H. Miki, Y. Okada, N. Hirokawa, Analysis of the kinesin superfamily: insights into structure and function, *Trends Cell Biol.* 15 (2005) 467–476. <https://doi.org/10.1016/j.tcb.2005.07.006>.
- [3] K.E. Sawin, T.J. Mitchison, L.G. Wordeman, Evidence for kinesin-related proteins in the mitotic apparatus using peptide antibodies, *J. Cell. Sci.* 101 ( Pt 2) (1992) 303–313.
- [4] K.E. Sawin, K. LeGuellec, M. Philippe, T.J. Mitchison, Mitotic spindle organization by a plus-end-directed microtubule motor, *Nature.* 359 (1992) 540–543. <https://doi.org/10.1038/359540a0>.
- [5] A. Blangy, H.A. Lane, P. d’Hérin, M. Harper, M. Kress, E.A. Nigg, Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo, *Cell.* 83 (1995) 1159–1169. [https://doi.org/10.1016/0092-8674\(95\)90142-6](https://doi.org/10.1016/0092-8674(95)90142-6).
- [6] G.-Y. Chen, J.M. Cleary, A.B. Asenjo, Y. Chen, J.A. Mascaro, D.F.J. Arginteanu, H. Sosa, W.O. Hancock, Kinesin-5 Promotes Microtubule Nucleation and Assembly by Stabilizing a Lattice-Competent Conformation of Tubulin, *Curr. Biol.* 29 (2019) 2259-2269.e4. <https://doi.org/10.1016/j.cub.2019.05.075>.
- [7] Y. Wakana, J. Villeneuve, J. van Galen, D. Cruz-Garcia, M. Tagaya, V. Malhotra, Kinesin-5/Eg5 is important for transport of CARTS from the trans-Golgi network to the cell surface, *J. Cell Biol.* 202 (2013) 241–250. <https://doi.org/10.1083/jcb.201303163>.
- [8] K.M. Bartoli, J. Jakovljevic, J.L. Woolford, W.S. Saunders, Kinesin molecular motor Eg5 functions during polypeptide synthesis, *Mol. Biol. Cell.* 22 (2011) 3420–3430. <https://doi.org/10.1091/mbc.E11-03-0211>.
- [9] L. Ferhat, C. Cook, M. Chauviere, M. Harper, M. Kress, G.E. Lyons, P.W. Baas, Expression of the mitotic motor protein Eg5 in postmitotic neurons: implications for neuronal development, *J. Neurosci.* 18 (1998) 7822–7835.
- [10] A. Fahnkar, S. Tole, P.W. Baas, Kinesin-5, a mitotic microtubule-associated motor protein, modulates neuronal migration, *Mol. Biol. Cell.* 22 (2011) 1561–1574. <https://doi.org/10.1091/mbc.E10-11-0905>.
- [11] S.Y. Yoon, J.E. Choi, J.-W. Huh, O. Hwang, H.S. Lee, H.N. Hong, D. Kim, Monastrol, a selective inhibitor of the mitotic kinesin Eg5, induces a distinctive growth profile of dendrites and axons in primary cortical neuron cultures, *Cell Motil. Cytoskeleton.* 60 (2005) 181–190. <https://doi.org/10.1002/cm.20057>.
- [12] A.S. Kashlana, R.J. Baskin, D.G. Cole, K.P. Wedaman, W.M. Saxton, J.M. Scholey, A bipolar kinesin, *Nature.* 379 (1996) 270–272. <https://doi.org/10.1038/379270a0>.
- [13] S. Acar, D.B. Carlson, M.S. Budamagunta, V. Yarov-Yarovoy, J.J. Correia, M.R. Niñonuevo, W. Jia, L. Tao, J.A. Leary, J.C. Voss, J.E. Evans, J.M. Scholey, The bipolar assembly domain of the mitotic motor kinesin-5, *Nat Commun.* 4 (2013) 1343. <https://doi.org/10.1038/ncomms2348>.
- [14] J.E. Scholey, S. Nithianantham, J.M. Scholey, J. Al-Bassam, Structural basis for the assembly of the mitotic motor Kinesin-5 into bipolar tetramers, *Elife.* 3 (2014) e02217. <https://doi.org/10.7554/eLife.02217>.
- [15] T. Bodrug, E.M. Wilson-Kubalek, S. Nithianantham, A.F. Thompson, A. Alfieri, I. Gaska, J. Major, G. Debs, S. Inagaki, P. Gutierrez, L. Gheber, R.J. McKenney, C.V. Sindelar, R. Milligan, J. Stumpff, S.S. Rosenfeld, S.T. Forth, J. Al-Bassam, The kinesin-5 tail domain directly modulates the mechanochemical cycle of the motor domain for anti-parallel microtubule sliding, *Elife.* 9 (2020). <https://doi.org/10.7554/eLife.51131>.
- [16] M.T. Valentine, P.M. Fordyce, T.C. Krzysiak, S.P. Gilbert, S.M. Block, Individual dimers of the mitotic kinesin motor Eg5 step processively and support substantial loads in vitro, *Nat Cell Biol.* 8 (2006) 470–476. <https://doi.org/10.1038/ncb1394>.
- [17] B.J. Mann, P. Wadsworth, Kinesin-5 Regulation and Function in Mitosis, *Trends Cell Biol.*

29 (2019) 66–79. <https://doi.org/10.1016/j.tcb.2018.08.004>.

[18] T.U. Mayer, T.M. Kapoor, S.J. Haggarty, R.W. King, S.L. Schreiber, T.J. Mitchison, Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen, *Science*. 286 (1999) 971–974. <https://doi.org/10.1126/science.286.5441.971>.

[19] D. Weil, L. Garçon, M. Harper, D. Duménil, F. Dautry, M. Kress, Targeting the kinesin Eg5 to monitor siRNA transfection in mammalian cells, *BioTechniques*. 33 (2002) 1244–1248. <https://doi.org/10.2144/02336st01>.

[20] C. Zhu, J. Zhao, M. Bibikova, J.D. Levenson, E. Bossy-Wetzell, J.-B. Fan, R.T. Abraham, W. Jiang, Functional analysis of human microtubule-based motor proteins, the kinesins and dyneins, in mitosis/cytokinesis using RNA interference, *Mol. Biol. Cell*. 16 (2005) 3187–3199. <https://doi.org/10.1091/mbc.e05-02-0167>.

[21] M. Chauvière, C. Kress, M. Kress, Disruption of the mitotic kinesin Eg5 gene (*Kns11*) results in early embryonic lethality, *Biochem. Biophys. Res. Commun.* 372 (2008) 513–519. <https://doi.org/10.1016/j.bbrc.2008.04.177>.

[22] A. Castillo, M.J. Justice, The kinesin related motor protein, Eg5, is essential for maintenance of pre-implantation embryogenesis, *Biochem. Biophys. Res. Commun.* 357 (2007) 694–699. <https://doi.org/10.1016/j.bbrc.2007.04.021>.

[23] P. Ostergaard, M.A. Simpson, A. Mendola, P. Vasudevan, F.C. Connell, A. van Impel, A.T. Moore, B.L. Loeys, A. Ghalamkarpour, A. Onoufriadis, I. Martinez-Corral, S. Devery, J.G. Leroy, L. van Laer, A. Singer, M.G. Bialer, M. McEntagart, O. Quarrell, G. Brice, R.C. Trembath, S. Schulte-Merker, T. Makinen, M. Vikkula, P.S. Mortimer, S. Mansour, S. Jeffery, Mutations in *KIF11* cause autosomal-dominant microcephaly variably associated with congenital lymphedema and chorioretinopathy, *Am. J. Hum. Genet.* 90 (2012) 356–362. <https://doi.org/10.1016/j.ajhg.2011.12.018>.

[24] J.M. Robitaille, R.M. Gillett, M.A. LeBlanc, D. Gaston, M. Nightingale, M.P. Mackley, S. Parkash, J. Hathaway, A. Thomas, A. Ells, E.I. Traboulsi, E. Héon, M. Roy, S. Shalev, C.V. Fernandez, C. MacGillivray, K. Wallace, S. Fahiminiya, J. Majewski, C.R. McMaster, K. Bedard, Phenotypic overlap between familial exudative vitreoretinopathy and microcephaly, lymphedema, and chorioretinal dysplasia caused by *KIF11* mutations, *JAMA Ophthalmol.* 132 (2014) 1393–1399. <https://doi.org/10.1001/jamaophthalmol.2014.2814>.

[25] J. Birtel, T. Eisenberger, M. Gliem, P.L. Müller, P. Herrmann, C. Betz, D. Zahnleiter, C. Neuhaus, S. Lenzner, F.G. Holz, E. Mangold, H.J. Bolz, P. Charbel Issa, Clinical and genetic characteristics of 251 consecutive patients with macular and cone/cone-rod dystrophy, *Sci Rep.* 8 (2018) 4824. <https://doi.org/10.1038/s41598-018-22096-0>.

[26] P. Exertier, S. Javerzat, B. Wang, M. Franco, J. Herbert, N. Platonova, M. Winandy, N. Pujol, O. Nivelles, S. Ormenese, V. Godard, J. Becker, R. Bicknell, R. Pineau, J. Wilting, A. Bikfalvi, M. Hagedorn, Impaired angiogenesis and tumor development by inhibition of the mitotic kinesin Eg5, *Oncotarget*. 4 (2013) 2302–2316. <https://doi.org/10.18632/oncotarget.1490>.

[27] Y. Wang, P.M. Smallwood, J. Williams, J. Nathans, A mouse model for kinesin family member 11 (*Kif11*)-associated familial exudative vitreoretinopathy, *Hum. Mol. Genet.* 29 (2020) 1121–1131. <https://doi.org/10.1093/hmg/ddaa018>.

[28] G.M. Hansen, M.J. Justice, Activation of Hex and mEg5 by retroviral insertion may contribute to mouse B-cell leukemia, *Oncogene*. 18 (1999) 6531–6539. <https://doi.org/10.1038/sj.onc.1203023>.

[29] T. Saijo, G. Ishii, A. Ochiai, K. Yoh, K. Goto, K. Nagai, H. Kato, Y. Nishiwaki, N. Saijo, Eg5 expression is closely correlated with the response of advanced non-small cell lung cancer to antimetabolic agents combined with platinum chemotherapy, *Lung Cancer*. 54 (2006) 217–225. <https://doi.org/10.1016/j.lungcan.2006.06.018>.

[30] D. Sun, J. Lu, K. Ding, D. Bi, Z. Niu, Q. Cao, J. Zhang, S. Ding, The expression of Eg5 predicts a poor outcome for patients with renal cell carcinoma, *Med. Oncol.* 30 (2013) 476. <https://doi.org/10.1007/s12032-013-0476-0>.

[31] M.D. Wissing, E.S. De Morrée, V.O. Dezentjé, J.T. Buijs, R.R. De Krijger, V.T.H.B.M.

- Smit, W.M. Van Weerden, H. Gelderblom, G. van der Pluijm, Nuclear Eg5 (kinesin spindle protein) expression predicts docetaxel response and prostate cancer aggressiveness, *Oncotarget*. 5 (2014) 7357–7367. <https://doi.org/10.18632/oncotarget.1985>.
- [32] S. Ding, N. Xing, J. Lu, H. Zhang, K. Nishizawa, S. Liu, X. Yuan, Y. Qin, Y. Liu, O. Ogawa, H. Nishiyama, Overexpression of Eg5 predicts unfavorable prognosis in non-muscle invasive bladder urothelial carcinoma, *Int. J. Urol.* 18 (2011) 432–438. <https://doi.org/10.1111/j.1442-2042.2011.02751.x>.
- [33] M. Lu, H. Zhu, X. Wang, D. Zhang, L. Xiong, L. Xu, Y. You, The prognostic role of Eg5 expression in laryngeal squamous cell carcinoma, *Pathology*. 48 (2016) 214–218. <https://doi.org/10.1016/j.pathol.2016.02.008>.
- [34] L. Liu, X. Liu, M. Mare, A.S. Dumont, H. Zhang, D. Yan, Z. Xiong, Overexpression of Eg5 correlates with high grade astrocytic neoplasm, *J. Neurooncol.* 126 (2016) 77–80. <https://doi.org/10.1007/s11060-015-1954-3>.
- [35] X. Sun, X. Shi, X. Sun, Y. Luo, X. Wu, C. Yao, H. Yu, D. Li, M. Liu, J. Zhou, Dimethylenastron suppresses human pancreatic cancer cell migration and invasion in vitro via allosteric inhibition of mitotic kinesin Eg5, *Acta Pharmacol. Sin.* 32 (2011) 1543–1548. <https://doi.org/10.1038/aps.2011.130>.
- [36] M.D. Planas-Silva, I.S. Filatova, Estrogen-dependent regulation of Eg5 in breast cancer cells, *Anticancer Drugs*. 18 (2007) 773–779. <https://doi.org/10.1097/CAD.0b013e3280a02f2b>.
- [37] A. Castillo, H.C. Morse, V.L. Godfrey, R. Naeem, M.J. Justice, Overexpression of Eg5 causes genomic instability and tumor formation in mice, *Cancer Res.* 67 (2007) 10138–10147. <https://doi.org/10.1158/0008-5472.CAN-07-0326>.
- [38] M. Markman, Managing taxane toxicities, *Support Care Cancer*. 11 (2003) 144–147. <https://doi.org/10.1007/s00520-002-0405-9>.
- [39] A.I. Marcus, U. Peters, S.L. Thomas, S. Garrett, A. Zelnak, T.M. Kapoor, P. Giannakakou, Mitotic kinesin inhibitors induce mitotic arrest and cell death in Taxol-resistant and -sensitive cancer cells, *J. Biol. Chem.* 280 (2005) 11569–11577. <https://doi.org/10.1074/jbc.M413471200>.
- [40] H.B. El-Nassan, Advances in the discovery of kinesin spindle protein (Eg5) inhibitors as antitumor agents, *Eur J Med Chem.* 62 (2013) 614–631. <https://doi.org/10.1016/j.ejmech.2013.01.031>.
- [41] A.P. Enos, N.R. Morris, Mutation of a gene that encodes a kinesin-like protein blocks nuclear division in *A. nidulans*, *Cell*. 60 (1990) 1019–1027. [https://doi.org/10.1016/0092-8674\(90\)90350-n](https://doi.org/10.1016/0092-8674(90)90350-n).
- [42] D.D. Hackney, W. Jiang, Assays for kinesin microtubule-stimulated ATPase activity, *Methods Mol. Biol.* 164 (2001) 65–71.
- [43] R.A. Cross, The kinetic mechanism of kinesin, *Trends Biochem. Sci.* 29 (2004) 301–309. <https://doi.org/10.1016/j.tibs.2004.04.010>.
- [44] B. Gigant, W. Wang, B. Dreier, Q. Jiang, L. Pecqueur, A. Plückthun, C. Wang, M. Knossow, Structure of a kinesin-tubulin complex and implications for kinesin motility, *Nat. Struct. Mol. Biol.* 20 (2013) 1001–1007. <https://doi.org/10.1038/nsmb.2624>.
- [45] L. Cao, W. Wang, Q. Jiang, C. Wang, M. Knossow, B. Gigant, The structure of apo-kinesin bound to tubulin links the nucleotide cycle to movement, *Nat Commun.* 5 (2014) 5364. <https://doi.org/10.1038/ncomms6364>.
- [46] C.L. Parke, E.J. Wojcik, S. Kim, D.K. Worthylake, ATP hydrolysis in Eg5 kinesin involves a catalytic two-water mechanism, *J. Biol. Chem.* 285 (2010) 5859–5867. <https://doi.org/10.1074/jbc.M109.071233>.
- [47] J. Turner, R. Anderson, J. Guo, C. Beraud, R. Fletterick, R. Sakowicz, Crystal structure of the mitotic spindle kinesin Eg5 reveals a novel conformation of the neck-linker, *J. Biol. Chem.* 276 (2001) 25496–25502. <https://doi.org/10.1074/jbc.M100395200>.
- [48] S. DeBonis, D.A. Skoufias, L. Lebeau, R. Lopez, G. Robin, R.L. Margolis, R.H. Wade, F. Kozielski, In vitro screening for inhibitors of the human mitotic kinesin Eg5 with antimitotic and antitumor activities, *Mol. Cancer Ther.* 3 (2004) 1079–1090.

- [49] F. Kozielski, S. DeBonis, D.A. Skoufias, Screening for inhibitors of microtubule-associated motor proteins, *Methods Mol. Med.* 137 (2007) 189–207. [https://doi.org/10.1007/978-1-59745-442-1\\_14](https://doi.org/10.1007/978-1-59745-442-1_14).
- [50] Z. Maliga, J. Xing, H. Cheung, L.J. Juszczak, J.M. Friedman, S.S. Rosenfeld, A pathway of structural changes produced by monastrol binding to Eg5, *J. Biol. Chem.* 281 (2006) 7977–7982. <https://doi.org/10.1074/jbc.M511955200>.
- [51] H.Y.K. Kaan, V. Ulaganathan, O. Rath, H. Prokopcová, D. Dallinger, C.O. Kappe, F. Kozielski, Structural basis for inhibition of Eg5 by dihydropyrimidines: stereoselectivity of antimitotic inhibitors enastron, dimethylenastron and fluorastrol, *J. Med. Chem.* 53 (2010) 5676–5683. <https://doi.org/10.1021/jm100421n>.
- [52] I. Garcia-Saez, S. DeBonis, R. Lopez, F. Trucco, B. Rousseau, P. Thuéry, F. Kozielski, Structure of human Eg5 in complex with a new monastrol-based inhibitor bound in the R configuration, *J. Biol. Chem.* 282 (2007) 9740–9747. <https://doi.org/10.1074/jbc.M608883200>.
- [53] C.D. Cox, P.J. Coleman, M.J. Breslin, D.B. Whitman, R.M. Garbaccio, M.E. Fraley, C.A. Buser, E.S. Walsh, K. Hamilton, M.D. Schaber, R.B. Lobell, W. Tao, J.P. Davide, R.E. Diehl, M.T. Abrams, V.J. South, H.E. Huber, M. Torrent, T. Prueksaritanont, C. Li, D.E. Slaughter, E. Mahan, C. Fernandez-Metzler, Y. Yan, L.C. Kuo, N.E. Kohl, G.D. Hartman, Kinesin spindle protein (KSP) inhibitors. 9. Discovery of (2S)-4-(2,5-difluorophenyl)-n-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the treatment of taxane-refractory cancer, *J. Med. Chem.* 51 (2008) 4239–4252. <https://doi.org/10.1021/jm800386y>.
- [54] H.Y.K. Kaan, V. Ulaganathan, D.D. Hackney, F. Kozielski, An allosteric transition trapped in an intermediate state of a new kinesin-inhibitor complex, *Biochem. J.* 425 (2009) 55–60. <https://doi.org/10.1042/BJ20091207>.
- [55] S.K. Talapatra, A.W. Schüttelkopf, F. Kozielski, The structure of the ternary Eg5-ADP-ispinesib complex, *Acta Crystallogr. D Biol. Crystallogr.* 68 (2012) 1311–1319. <https://doi.org/10.1107/S0907444912027965>.
- [56] S.K. Talapatra, N.G. Anthony, S.P. Mackay, F. Kozielski, Mitotic kinesin Eg5 overcomes inhibition to the phase I/II clinical candidate SB743921 by an allosteric resistance mechanism, *J. Med. Chem.* 56 (2013) 6317–6329. <https://doi.org/10.1021/jm4006274>.
- [57] R. Nakai, S. Iida, T. Takahashi, T. Tsujita, S. Okamoto, C. Takada, K. Akasaka, S. Ichikawa, H. Ishida, H. Kusaka, S. Akinaga, C. Murakata, S. Honda, M. Nitta, H. Saya, Y. Yamashita, K858, a novel inhibitor of mitotic kinesin Eg5 and antitumor agent, induces cell death in cancer cells, *Cancer Res.* 69 (2009) 3901–3909. <https://doi.org/10.1158/0008-5472.CAN-08-4373>.
- [58] S.K. Talapatra, C.L. Tham, P. Guglielmi, R. Cirilli, B. Chandrasekaran, R. Karpoornath, S. Carradori, F. Kozielski, Crystal structure of the Eg5 - K858 complex and implications for structure-based design of thiadiazole-containing inhibitors, *Eur J Med Chem.* 156 (2018) 641–651. <https://doi.org/10.1016/j.ejmech.2018.07.006>.
- [59] R.-L. Indorato, S.K. Talapatra, F. Lin, S. Haider, S.P. Mackay, F. Kozielski, D.A. Skoufias, Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5-Inhibitor Complexes, *Mol. Cancer Ther.* 18 (2019) 2394–2406. <https://doi.org/10.1158/1535-7163.MCT-19-0154>.
- [60] L. Luo, C.A. Parrish, N. Nevins, D.E. McNulty, A.M. Chaudhari, J.D. Carson, V. Sudakin, A.N. Shaw, R. Lehr, H. Zhao, S. Sweitzer, L. Lad, K.W. Wood, R. Sakowicz, R.S. Annan, P.S. Huang, J.R. Jackson, D. Dhanak, R.A. Copeland, K.R. Auger, ATP-competitive inhibitors of the mitotic kinesin KSP that function via an allosteric mechanism, *Nat. Chem. Biol.* 3 (2007) 722–726. <https://doi.org/10.1038/nchembio.2007.34>.
- [61] K. Matsuno, J. Sawada, M. Sugimoto, N. Ogo, A. Asai, Bis(hetero)aryl derivatives as unique kinesin spindle protein inhibitors, *Bioorg. Med. Chem. Lett.* 19 (2009) 1058–1061. <https://doi.org/10.1016/j.bmcl.2009.01.018>.
- [62] V. Ulaganathan, S.K. Talapatra, O. Rath, A. Pannifer, D.D. Hackney, F. Kozielski,

Structural insights into a unique inhibitor binding pocket in kinesin spindle protein, *J. Am. Chem. Soc.* 135 (2013) 2263–2272. <https://doi.org/10.1021/ja310377d>.

[63] A. Peña, A. Sweeney, A.D. Cook, J. Locke, M. Topf, C.A. Moores, Structure of Microtubule-Trapped Human Kinesin-5 and Its Mechanism of Inhibition Revealed Using Cryoelectron Microscopy, *Structure*. 28 (2020) 450-457.e5. <https://doi.org/10.1016/j.str.2020.01.013>.

[64] H. Yokoyama, J. Sawada, S. Katoh, K. Matsuno, N. Ogo, Y. Ishikawa, H. Hashimoto, S. Fujii, A. Asai, Structural basis of new allosteric inhibition in Kinesin spindle protein Eg5, *ACS Chem. Biol.* 10 (2015) 1128–1136. <https://doi.org/10.1021/cb500939x>.

[65] S. Chattopadhyay, A.L. Stewart, S. Mukherjee, C. Huang, K.A. Hartwell, P.G. Miller, R. Subramanian, L.C. Carmody, R.Z. Yusuf, D.B. Sykes, J. Paulk, A. Vetere, S. Vallet, L. Santo, D.D. Cirstea, T. Hideshima, V. Dančik, M.M. Majireck, M.M. Hussain, S. Singh, R. Quiroz, J. Iaconelli, R. Karmacharya, N.J. Tolliday, P.A. Clemons, M.A.S. Moore, A.M. Stern, A.F. Shamji, B.L. Ebert, T.R. Golub, N.S. Raje, D.T. Scadden, S.L. Schreiber, Niche-Based Screening in Multiple Myeloma Identifies a Kinesin-5 Inhibitor with Improved Selectivity over Hematopoietic Progenitors, *Cell Rep.* 10 (2015) 755–770. <https://doi.org/10.1016/j.celrep.2015.01.017>.

[66] J. Nakazawa, J. Yajima, T. Usui, M. Ueki, A. Takatsuki, M. Imoto, Y.Y. Toyoshima, H. Osada, A novel action of terpendole E on the motor activity of mitotic Kinesin Eg5, *Chem. Biol.* 10 (2003) 131–137. [https://doi.org/10.1016/s1074-5521\(03\)00020-6](https://doi.org/10.1016/s1074-5521(03)00020-6).

[67] J.G. Sheff, F. Farshidfar, O.F. Bathe, K. Kopciuk, F. Gentile, J. Tuszynski, K. Barakat, D.C. Schriemer, Novel Allosteric Pathway of Eg5 Regulation Identified through Multivariate Statistical Analysis of Hydrogen-Exchange Mass Spectrometry (HX-MS) Ligand Screening Data, *Mol. Cell Proteomics*. 16 (2017) 428–437. <https://doi.org/10.1074/mcp.M116.064246>.

[68] Y. Tarui, T. Chinen, Y. Nagumo, T. Motoyama, T. Hayashi, H. Hirota, M. Muroi, Y. Ishii, H. Kondo, H. Osada, T. Usui, Terpendole E and its derivative inhibit STLC- and GSK-1-resistant Eg5, *Chembiochem*. 15 (2014) 934–938. <https://doi.org/10.1002/cbic.201300808>.

[69] R. Sakowicz, M.S. Berdelis, K. Ray, C.L. Blackburn, C. Hopmann, D.J. Faulkner, L.S. Goldstein, A marine natural product inhibitor of kinesin motors, *Science*. 280 (1998) 292–295. <https://doi.org/10.1126/science.280.5361.292>.

[70] S. Brier, E. Carletti, S. DeBonis, E. Hewat, D. Lemaire, F. Kozielski, The marine natural product adociasulfate-2 as a tool to identify the MT-binding region of kinesins, *Biochemistry*. 45 (2006) 15644–15653. <https://doi.org/10.1021/bi061395n>.

[71] K.G. Reddie, D.R. Roberts, T.M. Dore, Inhibition of kinesin motor proteins by adociasulfate-2, *J. Med. Chem.* 49 (2006) 4857–4860. <https://doi.org/10.1021/jm060115z>.

[72] B. Wang, L. Chen, Z. Ni, X. Dai, L. Qin, Y. Wu, X. Li, L. Xu, J. Lian, F. He, Hsp90 inhibitor 17-AAG sensitizes Bcl-2 inhibitor (-)-gossypol by suppressing ERK-mediated protective autophagy and Mcl-1 accumulation in hepatocellular carcinoma cells, *Exp. Cell Res.* 328 (2014) 379–387. <https://doi.org/10.1016/j.yexcr.2014.08.039>.

[73] C.L. Oliver, M.B. Miranda, S. Shangary, S. Land, S. Wang, D.E. Johnson, (-)-Gossypol acts directly on the mitochondria to overcome Bcl-2- and Bcl-X(L)-mediated apoptosis resistance, *Mol. Cancer Ther.* 4 (2005) 23–31.

[74] K. Mansouri, S. Rasoulpoor, A. Daneshkhah, S. Abolfathi, N. Salari, M. Mohammadi, S. Rasoulpoor, S. Shabani, Clinical effects of curcumin in enhancing cancer therapy: A systematic review, *BMC Cancer*. 20 (2020) 791. <https://doi.org/10.1186/s12885-020-07256-8>.

[75] D. Raghav, J. Sebastian, K. Rathinasamy, Biochemical and Biophysical characterization of curcumin binding to human mitotic kinesin Eg5: Insights into the inhibitory mechanism of curcumin on Eg5, *Int. J. Biol. Macromol.* 109 (2018) 1189–1208. <https://doi.org/10.1016/j.ijbiomac.2017.11.115>.

[76] T.C. Roberts, R. Langer, M.J.A. Wood, Advances in oligonucleotide drug delivery, *Nat Rev Drug Discov.* (2020). <https://doi.org/10.1038/s41573-020-0075-7>.

[77] E. Koller, S. Propp, H. Zhang, C. Zhao, X. Xiao, M. Chang, S.A. Hirsch, P.J. Shepard, S. Koo, C. Murphy, R.I. Glazer, N.M. Dean, Use of a chemically modified antisense oligonucleotide

library to identify and validate Eg5 (kinesin-like 1) as a target for antineoplastic drug development, *Cancer Res.* 66 (2006) 2059–2066. <https://doi.org/10.1158/0008-5472.CAN-05-1531>.

[78] J. Taberero, G.I. Shapiro, P.M. LoRusso, A. Cervantes, G.K. Schwartz, G.J. Weiss, L. Paz-Ares, D.C. Cho, J.R. Infante, M. Alsina, M.M. Gounder, R. Falzone, J. Harrop, A.C.S. White, I. Toudjarska, D. Bumcrot, R.E. Meyers, G. Hinkle, N. Svzrikapa, R.M. Hutabarat, V.A. Clausen, J. Cehelsky, S.V. Nochur, C. Gamba-Vitalo, A.K. Vaishnaw, D.W.Y. Sah, J.A. Gollob, H.A. Burris, First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement, *Cancer Discov.* 3 (2013) 406–417. <https://doi.org/10.1158/2159-8290.CD-12-0429>.

[79] S. Seraj, J. Lee, H.J. Ahn, Systemic delivery of Eg5 shRNA-expressing plasmids using PEGylated DC-Chol/DOPE cationic liposome: Long-term silencing and anticancer effects in vivo, *Biochem. Pharmacol.* 166 (2019) 192–202. <https://doi.org/10.1016/j.bcp.2019.05.021>.

[80] K.E. Gascoigne, S.S. Taylor, How do anti-mitotic drugs kill cancer cells?, *J. Cell. Sci.* 122 (2009) 2579–2585. <https://doi.org/10.1242/jcs.039719>.

[81] J. Shi, T.J. Mitchison, Cell death response to anti-mitotic drug treatment in cell culture, mouse tumor model and the clinic, *Endocr. Relat. Cancer.* 24 (2017) T83–T96. <https://doi.org/10.1530/ERC-17-0003>.

[82] A.C. Henriques, D. Ribeiro, J. Pedrosa, B. Sarmento, P.M.A. Silva, H. Bousbaa, Mitosis inhibitors in anticancer therapy: When blocking the exit becomes a solution, *Cancer Letters.* 440–441 (2019) 64–81. <https://doi.org/10.1016/j.canlet.2018.10.005>.

[83] K.E. Gascoigne, S.S. Taylor, Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs, *Cancer Cell.* 14 (2008) 111–122. <https://doi.org/10.1016/j.ccr.2008.07.002>.

[84] J. Shi, J.D. Orth, T. Mitchison, Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5, *Cancer Res.* 68 (2008) 3269–3276. <https://doi.org/10.1158/0008-5472.CAN-07-6699>.

[85] J.D. Orth, Y. Tang, J. Shi, C.T. Loy, C. Amendt, C. Wilm, F.T. Zenke, T.J. Mitchison, Quantitative live imaging of cancer and normal cells treated with Kinesin-5 inhibitors indicates significant differences in phenotypic responses and cell fate, *Mol. Cancer Ther.* 7 (2008) 3480–3489. <https://doi.org/10.1158/1535-7163.MCT-08-0684>.

[86] D.D. Von Hoff, The taxoids: same roots, different drugs, *Semin. Oncol.* 24 (1997) S13–S13-10.

[87] M. Kavallaris, D.Y. Kuo, C.A. Burkhart, D.L. Regl, M.D. Norris, M. Haber, S.B. Horwitz, Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes, *J. Clin. Invest.* 100 (1997) 1282–1293. <https://doi.org/10.1172/JCI119642>.

[88] R.T. Lee, K.E. Beekman, M. Hussain, N.B. Davis, J.I. Clark, S.P. Thomas, K.F. Nichols, W.M. Stadler, A University of Chicago consortium phase II trial of SB-715992 in advanced renal cell cancer, *Clin Genitourin Cancer.* 6 (2008) 21–24. <https://doi.org/10.3816/CGC.2008.n.003>.

[89] D.A. Bradley, M. Hussain, Promising novel cytotoxic agents and combinations in metastatic prostate cancer, *Cancer J.* 14 (2008) 15–19. <https://doi.org/10.1097/PPO.0b013e31816220b7>.

[90] T.M. Beer, B. Goldman, T.W. Synold, C.W. Ryan, L.S. Vasist, P.J. Van Veldhuizen, S.R. Dakhil, P.N. Lara, A. Drelichman, M.H.A. Hussain, E.D. Crawford, Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanes, *Clin Genitourin Cancer.* 6 (2008) 103–109. <https://doi.org/10.3816/CGC.2008.n.016>.

[91] J.J. Knox, S. Gill, T.W. Synold, J.J. Biagi, P. Major, R. Feld, C. Cripps, N. Wainman, E. Eisenhauer, L. Seymour, A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168), *Invest New Drugs.* 26 (2008) 265–272. <https://doi.org/10.1007/s10637-007-9103-2>.

[92] C.W. Lee, K. Bélanger, S.C. Rao, T.M. Petrella, R.G. Tozer, L. Wood, K.J. Savage, E.A. Eisenhauer, T.W. Synold, N. Wainman, L. Seymour, A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada

Clinical Trials Group trial, *Invest New Drugs*. 26 (2008) 249–255. <https://doi.org/10.1007/s10637-007-9097-9>.

[93] P.A. Tang, L.L. Siu, E.X. Chen, S.J. Hotte, S. Chia, J.K. Schwarz, G.R. Pond, C. Johnson, A.D. Colevas, T.W. Synold, L.S. Vasist, E. Winqvist, Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck, *Invest New Drugs*. 26 (2008) 257–264. <https://doi.org/10.1007/s10637-007-9098-8>.

[94] Jackson, J. R., Auger, K. R., Gilmartin, A., Wai, E. K., Luo, L., Concha, N., Parrish, C. A., Sutton, D., Diamond, M. A., Giardiniere, M., Zhang, S.-Y., Huang, P. S., Wood, K. W., Belmont, L., Lee, Y., Bergnes, G., Anderson, R., Brejc, K. and Sakowicz, R., A resistance mechanism for the KSP inhibitor ispinesib implicates point mutations in the compound binding site, *Proceedings of the AAC-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting*, AACR, Philadelphia, PA. (2005).

[95] O.A. O'Connor, J. Gerecitano, H. Van Deventer, J. Hainsworth, K.M. Zullo, K. Saikali, J. Seroogy, A. Wolff, R. Escandón, The addition of granulocyte-colony stimulating factor shifts the dose limiting toxicity and markedly increases the maximum tolerated dose and activity of the kinesin spindle protein inhibitor SB-743921 in patients with relapsed or refractory lymphoma: results of an international, multicenter phase I/II study, *Leuk. Lymphoma*. 56 (2015) 2585–2591. <https://doi.org/10.3109/10428194.2015.1004167>.

[96] M.-E. Theoclitou, B. Aquila, M.H. Block, P.J. Brassil, L. Castriotta, E. Code, M.P. Collins, A.M. Davies, T. Deegan, J. Ezhuthachan, S. Filla, E. Freed, H. Hu, D. Huszar, M. Jayaraman, D. Lawson, P.M. Lewis, M.V.P. Nadella, V. Oza, M. Padmanilayam, T. Pontz, L. Ronco, D. Russell, D. Whitston, X. Zheng, Discovery of (+)-N-(3-aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide (AZD4877), a kinesin spindle protein inhibitor and potential anticancer agent, *J. Med. Chem.* 54 (2011) 6734–6750. <https://doi.org/10.1021/jm200629m>.

[97] J.F. Gerecitano, J.J. Stephenson, N.L. Lewis, A. Osmukhina, J. Li, K. Wu, Z. You, D. Huszar, J.M. Skolnik, G.K. Schwartz, A Phase I trial of the kinesin spindle protein (Eg5) inhibitor AZD4877 in patients with solid and lymphoid malignancies, *Invest New Drugs*. 31 (2013) 355–362. <https://doi.org/10.1007/s10637-012-9821-y>.

[98] R. Jones, J. Vuky, T. Elliott, G. Mead, J.A. Arranz, J. Chester, S. Chowdhury, A.Z. Dudek, V. Müller-Mattheis, M.-O. Grimm, J.E. Gschwend, C. Wülfing, P. Albers, J. Li, A. Osmukhina, J. Skolnik, G. Hudes, Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer, *Invest New Drugs*. 31 (2013) 1001–1007. <https://doi.org/10.1007/s10637-013-9926-y>.

[99] H.M. Kantarjian, S. Padmanabhan, W. Stock, M.S. Tallman, G.A. Curt, J. Li, A. Osmukhina, K. Wu, D. Huszar, G. Borthukar, S. Faderl, G. Garcia-Manero, T. Kadia, K. Sankhala, O. Odenike, J.K. Altman, M. Minden, Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia, *Invest New Drugs*. 30 (2012) 1107–1115. <https://doi.org/10.1007/s10637-011-9660-2>.

[100] S. Jeay, S. Ali, C.-R. Chen, U. Uppalapati, D. Senator, T. Chan, D. France, M. Ashwell, Discovery of a novel Eg5 kinesin inhibitor, ARQ 621, with potent antitumor activity while sparing bone marrow-derived cells, *Cancer Res*. 68 (2008) 656.

[101] L.C. Chen, L.S. Rosen, T. Iyengar, J.W. Goldman, R. Savage, J. Kazakin, T.C.K. Chan, B.E. Schwartz, G. Abbadessa, D.D. Von Hoff, First-in-human study with ARQ 621, a novel inhibitor of Eg5: Final results from the solid tumors cohort., *JCO*. 29 (2011) 3076–3076. [https://doi.org/10.1200/jco.2011.29.15\\_suppl.3076](https://doi.org/10.1200/jco.2011.29.15_suppl.3076).

[102] K. Holen, R. DiPaola, G. Liu, A.R. Tan, G. Wilding, K. Hsu, N. Agrawal, C. Chen, L. Xue, E. Rosenberg, M. Stein, A phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumors, *Invest New Drugs*. 30 (2012) 1088–1095. <https://doi.org/10.1007/s10637-011-9653-1>.

[103] X.S. Ye, L. Fan, R.D. Van Horn, R. Nakai, Y. Ohta, S. Akinaga, C. Murakata, Y. Yamashita, T. Yin, K.M. Credille, G.P. Donoho, F.F. Merzoug, H. Li, A. Aggarwal, K. Blanchard,



E.H. Westin, A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor Models, *Mol. Cancer Ther.* 14 (2015) 2463–2472. <https://doi.org/10.1158/1535-7163.MCT-15-0241>.

[104] J.R. Infante, A. Patnaik, C.F. Verschraegen, A.J. Olszanski, M. Shaheen, H.A. Burris, A.W. Tolcher, K.P. Papadopoulos, M. Beeram, S.M. Hynes, J. Leohr, A.B. Lin, L.Q. Li, A. McGlothlin, D.L. Farrington, E.H. Westin, R.B. Cohen, Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer, *Cancer Chemother. Pharmacol.* 79 (2017) 315–326. <https://doi.org/10.1007/s00280-016-3205-5>.

[105] H. Wakui, N. Yamamoto, S. Kitazono, H. Mizugaki, S. Nakamichi, Y. Fujiwara, H. Nokihara, Y. Yamada, K. Suzuki, H. Kanda, S. Akinaga, T. Tamura, A phase 1 and dose-finding study of LY2523355 (litronesib), an Eg5 inhibitor, in Japanese patients with advanced solid tumors, *Cancer Chemother. Pharmacol.* 74 (2014) 15–23. <https://doi.org/10.1007/s00280-014-2467-z>.

[106] R. Woessner, B. Tunquist, C. Lemieux, E. Chlipala, S. Jackinsky, W. Dewolf, W. Voegtli, A. Cox, S. Rana, P. Lee, D. Walker, ARRY-520, a novel KSP inhibitor with potent activity in hematological and taxane-resistant tumor models, *Anticancer Res.* 29 (2009) 4373–4380.

[107] B. Owens, Kinesin inhibitor marches toward first-in-class pivotal trial, *Nat. Med.* 19 (2013) 1550. <https://doi.org/10.1038/nm1213-1550a>.

[108] E.M. Algarín, S. Hernández-García, M. Garayoa, E.M. Ocio, Filanesib for the treatment of multiple myeloma, *Expert Opin Investig Drugs.* 29 (2020) 5–14. <https://doi.org/10.1080/13543784.2020.1703179>.

[109] J.J. Shah, J.L. Kaufman, J.A. Zonder, A.D. Cohen, W.I. Bensinger, B.W. Hilder, S.A. Rush, D.H. Walker, B.J. Tunquist, K.S. Litwiler, M. Ptaszynski, R.Z. Orlowski, S. Lonial, A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma, *Cancer.* 123 (2017) 4617–4630. <https://doi.org/10.1002/cncr.30892>.

[110] A. Chari, M. Htut, J.A. Zonder, J.W. Fay, A.J. Jakubowiak, J.B. Levy, K. Lau, S.M. Burt, B.J. Tunquist, B.W. Hilder, S.A. Rush, D.H. Walker, M. Ptaszynski, J.L. Kaufman, A phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma, *Cancer.* 122 (2016) 3327–3335. <https://doi.org/10.1002/cncr.30174>.

[111] H.C. Lee, J.J. Shah, L. Feng, E.E. Manasanch, R. Lu, A. Morphey, B. Crumpton, K.K. Patel, M.L. Wang, R. Alexanian, S.K. Thomas, D.M. Weber, R.Z. Orlowski, A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma, *Blood Cancer J.* 9 (2019) 80. <https://doi.org/10.1038/s41408-019-0240-6>.

[112] J.A. Zonder, S. Usmani, E.C. Scott, C.C. Hofmeister, N. Lendvai, J.G. Berdeja, L.D. Anderson, P. Hari, S. Singhal, G. Orloff, M. Craig, J. Valent, W. Lee, L. Hart, J. Hrom, S. Tarantolo, E. Faber, G.J. Schiller, J. Schreiber, C. Oliver, S.A. Rush, B. Tunquist, M. Ptaszynski, N.S. Raje, Phase 2 Study of Carfilzomib (CFZ) with or without Filanesib (FIL) in Patients with Advanced Multiple Myeloma (MM), *Blood.* 126 (2015) 728–728. <https://doi.org/10.1182/blood.V126.23.728.728>.

[113] E.M. Ocio, C. Motlló, P. Rodríguez-Otero, J. Martínez-López, M.J. Cejalvo, J. Martín-Sánchez, J. Bladé, M.D. García-Malo, M.V. Dourdil, A. García-Mateo, F. de Arriba, R. García-Sanz, J. de la Rubia, A. Oriol, J.-J. Lahuerta, J.F. San-Miguel, M.-V. Mateos, Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1-acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group, *Br. J. Haematol.* (2020). <https://doi.org/10.1111/bjh.16788>.

[114] Y.N. Lamb, Daratumumab: A Review in Combination Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma, *Drugs.* (2020). <https://doi.org/10.1007/s40265-020-01385-x>.

[115] S.S. Rosenfeld, Clinical trials of mitotic kinesin inhibitors, in: *Kinesins and Cancer, 2015:* pp. 63–76. [https://doi.org/10.1007/978-94-017-9732-0\\_4](https://doi.org/10.1007/978-94-017-9732-0_4).

[116] E. Komlodi-Pasztor, D.L. Sackett, A.T. Fojo, Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a flawed rationale, *Clin. Cancer Res.* 18 (2012) 51–63. <https://doi.org/10.1158/1078-0432.CCR-11-0999>.

- [117] T.J. Mitchison, The proliferation rate paradox in antimetabolic chemotherapy, *Mol. Biol. Cell.* 23 (2012) 1–6. <https://doi.org/10.1091/mbc.E10-04-0335>.
- [118] K.B. Mross, D. Scharr, H. Richly, A. Frost, S. Bauer, B. Krauss, R. Krauss, A. Mais, B. Hauns, B. Hentsch, R. Baumgartner, M.E. Scheulen, First-in-human study of 4SC-205 (AEGIS), a novel oral inhibitor of Eg5 kinesin spindle protein., *JCO.* 32 (2014) 2564–2564. [https://doi.org/10.1200/jco.2014.32.15\\_suppl.2564](https://doi.org/10.1200/jco.2014.32.15_suppl.2564).
- [119] N. McGranahan, C. Swanton, Biological and therapeutic impact of intratumor heterogeneity in cancer evolution, *Cancer Cell.* 27 (2015) 15–26. <https://doi.org/10.1016/j.ccell.2014.12.001>.
- [120] C. Kasap, O. Elemento, T.M. Kapoor, DrugTargetSeqR: a genomics- and CRISPR-Cas9-based method to analyze drug targets, *Nat. Chem. Biol.* 10 (2014) 626–628. <https://doi.org/10.1038/nchembio.1551>.
- [121] S.A. Wacker, B.R. Houghtaling, O. Elemento, T.M. Kapoor, Using transcriptome sequencing to identify mechanisms of drug action and resistance, *Nature Chemical Biology.* 8 (2012) 235–237. <https://doi.org/10.1038/nchembio.779>.
- [122] E.G. Sturgill, S.R. Norris, Y. Guo, R. Ohi, Kinesin-5 inhibitor resistance is driven by kinesin-12, *J. Cell Biol.* 213 (2016) 213–227. <https://doi.org/10.1083/jcb.201507036>.
- [123] W.M. Behnke-Parks, J. Vendome, B. Honig, Z. Maliga, C. Moores, S.S. Rosenfeld, Loop L5 Acts as a Conformational Latch in the Mitotic Kinesin Eg5, *J. Biol. Chem.* 286 (2011) 5242–5253. <https://doi.org/10.1074/jbc.M110.192930>.
- [124] E.D. Kim, R. Buckley, S. Learman, J. Richard, C. Parke, D.K. Worthylake, E.J. Wojcik, R.A. Walker, S. Kim, Allosteric drug discrimination is coupled to mechanochemical changes in the kinesin-5 motor core, *J. Biol. Chem.* 285 (2010) 18650–18661. <https://doi.org/10.1074/jbc.M109.092072>.
- [125] Z. Maliga, T.J. Mitchison, Small-molecule and mutational analysis of allosteric Eg5 inhibition by monastrol, *BMC Chem Biol.* 6 (2006) 2. <https://doi.org/10.1186/1472-6769-6-2>.
- [126] S. Brier, D. Lemaire, S. DeBonis, E. Forest, F. Kozielski, Molecular dissection of the inhibitor binding pocket of mitotic kinesin Eg5 reveals mutants that confer resistance to antimetabolic agents, *J. Mol. Biol.* 360 (2006) 360–376. <https://doi.org/10.1016/j.jmb.2006.04.062>.
- [127] P.R. Sheth, G.W. Shipps, W. Seghezzi, C.K. Smith, C.-C. Chuang, D. Sanden, A.D. Basso, L. Vilenchik, K. Gray, D.A. Annis, E. Nickbarg, Y. Ma, B. Lahue, R. Herbst, H.V. Le, Novel Benzimidazole Inhibitors Bind to a Unique Site in the Kinesin Spindle Protein Motor Domain, *Biochemistry.* 49 (2010) 8350–8358. <https://doi.org/10.1021/bi1005283>.
- [128] C.G. Marshall, M. Torrent, O. Williams, K.A. Hamilton, C.A. Buser, Characterization of inhibitor binding to human kinesin spindle protein by site-directed mutagenesis, *Arch. Biochem. Biophys.* 484 (2009) 1–7. <https://doi.org/10.1016/j.abb.2009.01.015>.
- [129] R.-L. Indorato, S. DeBonis, F. Kozielski, I. Garcia-Saez, D.A. Skoufias, STLC-resistant cell lines as tools to classify chemically divergent Eg5 targeting agents according to their mode of action and target specificity, *Biochem. Pharmacol.* 86 (2013) 1441–1451. <https://doi.org/10.1016/j.bcp.2013.09.003>.
- [130] S. Tcherniuk, R. van Lis, F. Kozielski, D.A. Skoufias, Mutations in the human kinesin Eg5 that confer resistance to monastrol and S-trityl-L-cysteine in tumor derived cell lines, *Biochem. Pharmacol.* 79 (2010) 864–872. <https://doi.org/10.1016/j.bcp.2009.11.001>.
- [131] D. Vanneste, M. Takagi, N. Imamoto, I. Vernos, The role of Hk1p2 in the stabilization and maintenance of spindle bipolarity, *Curr. Biol.* 19 (2009) 1712–1717. <https://doi.org/10.1016/j.cub.2009.09.019>.
- [132] M.E. Tanenbaum, L. Macûrek, A. Janssen, E.F. Geers, M. Alvarez-Fernández, R.H. Medema, Kif15 cooperates with eg5 to promote bipolar spindle assembly, *Curr. Biol.* 19 (2009) 1703–1711. <https://doi.org/10.1016/j.cub.2009.08.027>.
- [133] M.E. Dumas, G.-Y. Chen, N.D. Kendrick, G. Xu, S.D. Larsen, S. Jana, A.G. Waterson, J.A. Bauer, W. Hancock, G.A. Sulikowski, R. Ohi, Dual inhibition of Kif15 by oxindole and quinazolinedione chemical probes, *Bioorg. Med. Chem. Lett.* 29 (2019) 148–154. <https://doi.org/10.1016/j.bmcl.2018.12.008>.

- 1 [134] B. Milic, A. Chakraborty, K. Han, M.C. Bassik, S.M. Block, KIF15 nanomechanics and  
2 kinesin inhibitors, with implications for cancer chemotherapeutics, *Proc. Natl. Acad. Sci. U.S.A.*  
3 115 (2018) E4613–E4622. <https://doi.org/10.1073/pnas.1801242115>.
- 4 [135] J. Sebastian, K. Rathinasamy, Benserazide Perturbs Kif15-kinesin Binding Protein  
5 Interaction with Prolonged Metaphase and Defects in Chromosomal Congression: A Study Based  
6 on in silico Modeling and Cell Culture, *Mol Inform.* 39 (2020) e1900035.  
7 <https://doi.org/10.1002/minf.201900035>.
- 8 [136] H.T. Ma, S. Erdal, S. Huang, R.Y.C. Poon, Synergism between inhibitors of Aurora A and  
9 KIF11 overcomes KIF15-dependent drug resistance, *Mol Oncol.* 8 (2014) 1404–1418.  
10 <https://doi.org/10.1016/j.molonc.2014.05.007>.
- 11 [137] J.A. Raaijmakers, R.G.H.P. van Heesbeen, J.L. Meaders, E.F. Geers, B. Fernandez-Garcia,  
12 R.H. Medema, M.E. Tanenbaum, Nuclear envelope-associated dynein drives prophase centrosome  
13 separation and enables Eg5-independent bipolar spindle formation, *EMBO J.* 31 (2012) 4179–4190.  
14 <https://doi.org/10.1038/emboj.2012.272>.
- 15 [138] B.R. Mardin, M. Isokane, M.R. Cosenza, A. Krämer, J. Ellenberg, A.M. Fry, E. Schiebel,  
16 EGF-induced centrosome separation promotes mitotic progression and cell survival, *Dev. Cell.* 25  
17 (2013) 229–240. <https://doi.org/10.1016/j.devcel.2013.03.012>.
- 18 [139] H.J. Whalley, A.P. Porter, Z. Diamantopoulou, G.R.M. White, E. Castañeda-Saucedo, A.  
19 Malliri, Cdk1 phosphorylates the Rac activator Tiam1 to activate centrosomal Pak and promote  
20 mitotic spindle formation, *Nat Commun.* 6 (2015) 7437. <https://doi.org/10.1038/ncomms8437>.
- 21 [140] P. Khongorzul, C.J. Ling, F.U. Khan, A.U. Ihsan, J. Zhang, Antibody-Drug Conjugates: A  
22 Comprehensive Review, *Mol. Cancer Res.* 18 (2020) 3–19. <https://doi.org/10.1158/1541-7786.MCR-19-0582>.
- 23 [141] H.-G. Lerchen, B. Stelte-Ludwig, S. Berndt, A. Sommer, L. Dietz, A.-S. Rebstock, S.  
24 Johannes, L. Marx, H. Jörißen, C. Mahlert, S. Greven, Antibody-Prodrug Conjugates with KSP  
25 Inhibitors and Legumain-Mediated Metabolite Formation, *Chemistry.* 25 (2019) 8208–8213.  
26 <https://doi.org/10.1002/chem.201900441>.
- 27 [142] H.-G. Lerchen, S. Wittrock, B. Stelte-Ludwig, A. Sommer, S. Berndt, N. Griebenow, A.-S.  
28 Rebstock, S. Johannes, Y. Cancho-Grande, C. Mahlert, S. Greven, C. Terjung, Antibody-Drug  
29 Conjugates with Pyrrole-Based KSP Inhibitors as the Payload Class, *Angew. Chem. Int. Ed. Engl.*  
30 57 (2018) 15243–15247. <https://doi.org/10.1002/anie.201807619>.
- 31 [143] S. Johannes, S. Hammer, S. Maersch, H.-G. Lerchen, B. Stelte-Ludwig, H. Joerissen, O. von  
32 Ahsen, C. Schatz, S. Greven, C. Mahlert, D. Mumberg, P. Lejeune, Abstract 4825: Preclinical  
33 characterization of BAY-924, a first in class ADC targeting CXCR5-positive B-cell malignancies,  
34 with a KSP inhibitor as novel payload, *Cancer Res.* 79 (2019) 4825. <https://doi.org/10.1158/1538-7445.AM2019-4825>.
- 35 [144] S. Nagarajan, D.A. Skoufias, F. Kozielski, A.N. Pae, Receptor-ligand interaction-based  
36 virtual screening for novel Eg5/kinesin spindle protein inhibitors, *J. Med. Chem.* 55 (2012) 2561–  
37 2573. <https://doi.org/10.1021/jm201290v>.
- 38 [145] Y. Wang, X. Wu, M. Du, X. Chen, X. Ning, H. Chen, S. Wang, J. Liu, Z. Liu, R. Li, G. Fu,  
39 C. Wang, M.A. McNutt, D. Zhou, Y. Yin, Eg5 inhibitor YL001 induces mitotic arrest and inhibits  
40 tumor proliferation, *Oncotarget.* 8 (2017) 42510–42524. <https://doi.org/10.18632/oncotarget.17207>.
- 41 [146] C. Balakumar, M. Ramesh, C.L. Tham, S.P. Khathi, F. Kozielski, C. Srinivasulu, G.A.  
42 Hampannavar, N. Sayyad, M.E. Soliman, R. Karpoormath, Ligand- and structure-based in silico  
43 studies to identify kinesin spindle protein (KSP) inhibitors as potential anticancer agents, *J. Biomol.*  
44 *Struct. Dyn.* 36 (2018) 3687–3704. <https://doi.org/10.1080/07391102.2017.1396255>.
- 45 [147] J. Lyu, S. Wang, T.E. Balius, I. Singh, A. Levit, Y.S. Moroz, M.J. O’Meara, T. Che, E.  
46 Alga, K. Tolmacheva, A.A. Tolmachev, B.K. Shoichet, B.L. Roth, J.J. Irwin, Ultra-large library  
47 docking for discovering new chemotypes, *Nature.* 566 (2019) 224–229.  
48 <https://doi.org/10.1038/s41586-019-0917-9>.
- 49 [148] V.C. Nadar, A. Ketschek, K.A. Myers, G. Gallo, P.W. Baas, Kinesin-5 is essential for  
50 growth-cone turning, *Curr. Biol.* 18 (2008) 1972–1977. <https://doi.org/10.1016/j.cub.2008.11.021>.
- 51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

- [149] V.C. Nadar, S. Lin, P.W. Baas, Microtubule redistribution in growth cones elicited by focal inactivation of kinesin-5, *J. Neurosci.* 32 (2012) 5783–5794.  
<https://doi.org/10.1523/JNEUROSCI.0144-12.2012>.
- [150] S.A. Haque, T.P. Hasaka, A.D. Brooks, P.V. Lobanov, P.W. Baas, Monastrol, a prototype anti-cancer drug that inhibits a mitotic kinesin, induces rapid bursts of axonal outgrowth from cultured postmitotic neurons, *Cell Motil. Cytoskeleton.* 58 (2004) 10–16.  
<https://doi.org/10.1002/cm.10176>.
- [151] S. Lin, M. Liu, Y.-J. Son, B. Timothy Himes, D.M. Snow, W. Yu, P.W. Baas, Inhibition of Kinesin-5, a microtubule-based motor protein, as a strategy for enhancing regeneration of adult axons, *Traffic.* 12 (2011) 269–286. <https://doi.org/10.1111/j.1600-0854.2010.01152.x>.
- [152] M. Venere, C. Horbinski, J.F. Crish, X. Jin, A. Vasanji, J. Major, A.C. Burrows, C. Chang, J. Prokop, Q. Wu, P.A. Sims, P. Canoll, M.K. Summers, S.S. Rosenfeld, J.N. Rich, The mitotic kinesin KIF11 is a driver of invasion, proliferation, and self-renewal in glioblastoma, *Sci Transl Med.* 7 (2015) 304ra143. <https://doi.org/10.1126/scitranslmed.aac6762>.
- [153] G. Gampa, R.S. Kenchappa, A.S. Mohammad, K.E. Parrish, M. Kim, J.F. Crish, A. Luu, R. West, A.Q. Hinojosa, J.N. Sarkaria, S.S. Rosenfeld, W.F. Elmquist, Enhancing Brain Retention of a KIF11 Inhibitor Significantly Improves its Efficacy in a Mouse Model of Glioblastoma, *Sci Rep.* 10 (2020) 6524. <https://doi.org/10.1038/s41598-020-63494-7>.
- [154] A.D. Basso, M. Liu, C. Dai, K. Gray, L. Nale, S. Tevar, S. Lee, L. Liang, A. Ponery, B. Yaremko, E. Smith, H. Tang, P.R. Sheth, M.A. Siddiqui, D.J. Hicklin, P. Kirschmeier, SCH 2047069, a novel oral kinesin spindle protein inhibitor, shows single-agent antitumor activity and enhances the efficacy of chemotherapeutics, *Mol. Cancer Ther.* 9 (2010) 2993–3002.  
<https://doi.org/10.1158/1535-7163.MCT-10-0548>.
- [155] U.F. Mansoor, A.R. Angeles, C. Dai, L. Yang, D. Vitharana, A.D. Basso, K. Gray, H. Tang, M. Liu, L. Liang, O. Allbritton, M.A. Siddiqui, Discovery of novel spiro 1,3,4-thiadiazolines as potent, orally bioavailable and brain penetrant KSP inhibitors, *Bioorg. Med. Chem.* 23 (2015) 2424–2434. <https://doi.org/10.1016/j.bmc.2015.03.052>.
- [156] E. Terribas, M. Fernández, H. Mazuelas, J. Fernández-Rodríguez, J. Biayna, I. Blanco, G. Bernal, I. Ramos-Oliver, C. Thomas, R. Guha, X. Zhang, B. Gel, C. Romagosa, M. Ferrer, C. Lázaro, E. Serra, KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors, *Neurooncol Adv.* 2 (2020) i62–i74.  
<https://doi.org/10.1093/oaajnl/vdz061>.
- [157] A. Acar, D. Nichol, J. Fernandez-Mateos, G.D. Cresswell, I. Barozzi, S.P. Hong, N. Trahearn, I. Spiteri, M. Stubbs, R. Burke, A. Stewart, G. Caravagna, B. Werner, G. Vlachogiannis, C.C. Maley, L. Magnani, N. Valeri, U. Banerji, A. Sottoriva, Exploiting evolutionary steering to induce collateral drug sensitivity in cancer, *Nat Commun.* 11 (2020) 1923.  
<https://doi.org/10.1038/s41467-020-15596-z>.
- [158] P.R. Chua, D.M. Roof, Y. Lee, R. Sakowicz, D. Clarke, D. Pierce, T. Stephens, M. Hamilton, B. Morgan, D. Morgans, T. Nakai, A. Tomasi, M.E. Maxon, Effective killing of the human pathogen *Candida albicans* by a specific inhibitor of non-essential mitotic kinesin Kip1p, *Mol. Microbiol.* 65 (2007) 347–362. <https://doi.org/10.1111/j.1365-2958.2007.05787.x>.
- [159] O. von Loeffelholz, A. Peña, D.R. Drummond, R. Cross, C.A. Moores, Cryo-EM Structure (4.5-Å) of Yeast Kinesin-5-Microtubule Complex Reveals a Distinct Binding Footprint and Mechanism of Drug Resistance, *J. Mol. Biol.* 431 (2019) 864–872.  
<https://doi.org/10.1016/j.jmb.2019.01.011>.
- [160] O. von Loeffelholz, C.A. Moores, Cryo-EM structure of the *Ustilago maydis* kinesin-5 motor domain bound to microtubules, *J. Struct. Biol.* 207 (2019) 312–316.  
<https://doi.org/10.1016/j.jsb.2019.07.003>.
- [161] World malaria report 2019, (n.d.). <https://www.who.int/publications-detail-redirect/9789241565721> (accessed September 23, 2020).
- [162] L. Liu, J. Richard, S. Kim, E.J. Wojcik, Small molecule screen for candidate antimalarials targeting Plasmodium Kinesin-5, *J. Biol. Chem.* 289 (2014) 16601–16614.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

<https://doi.org/10.1074/jbc.M114.551408>.

[163] M. Zeeshan, D. Brady, R.R. Stanway, C. Moores, A.A. Holder, R. Tewari, Plasmodium berghei kinesin-5 associates with the spindle apparatus during cell division and is important for efficient production of infectious sporozoites, *BioRxiv*. (2020) 2020.07.03.186031.

<https://doi.org/10.1101/2020.07.03.186031>.

[164] T. Spangenberg, J.N. Burrows, P. Kowalczyk, S. McDonald, T.N.C. Wells, P. Willis, The Open Access Malaria Box: A Drug Discovery Catalyst for Neglected Diseases, *PLOS ONE*. 8 (2013) e62906. <https://doi.org/10.1371/journal.pone.0062906>.

[165] K. Schiemann, D. Finsinger, F. Zenke, C. Amendt, T. Knöchel, D. Bruge, H.-P. Buchstaller, U. Emde, W. Stähle, S. Anzali, The discovery and optimization of hexahydro-2H-pyrano[3,2-c]quinolines (HHPQs) as potent and selective inhibitors of the mitotic kinesin-5, *Bioorg. Med. Chem. Lett.* 20 (2010) 1491–1495. <https://doi.org/10.1016/j.bmcl.2010.01.110>.

## Figure Legends

1  
2 **Figure 1 A)** Schematic representation of antiparallel microtubule sliding by Eg5 tetramers. At  
3 each end of the Eg5 tetramer there is a dimer of motor domains that interact with  
4 microtubules moving towards the + ends of microtubules. The central helical bundle (BASS  
5 domain) formed by two antiparallel alpha helical coiled-coils is responsible for the  
6 tetramerization of Eg5. The C-terminus of each monomer interacts with the motor domain of  
7 the opposing monomer slowing the ATP binding to the motor and favoring the microtubule  
8 bound state of the motor.  
9

10  
11 **B)** A bipolar spindle of an untreated (left panel) and a monoastral spindle in  $\alpha$ -tubulin-GFP  
12 expressing HeLa cells treated with an Eg5 inhibitor (right panel), such as 10nM Arry-520  
13 [106].  
14

15  
16 **Figure 2** Eg5 inhibitors. Chemical structures of representative Eg5 motor domain inhibitors,  
17 arranged by chemical class or scaffolds. The KSPi-SMOL is chemically linked and used as a  
18 payload to an antibody drug conjugate. The thiazole, aminobenzylthiazole, inhibits  
19 preferentially the kinesin-5 member of the pathogen *C. albicans*, whereas the MMV666693  
20 was identified as a specific inhibitor of the kinesin-5 of the malaria parasites of the genus  
21 *Plasmodium*.  
22

23  
24 **Figure 3** Crystal structure of the Eg5 motor domain bound to Arry-520. **A)** Overall structure  
25 of the ternary  $Mg^{2+}$ -ADP-Eg5-Arry-520 complex showing the front view of the Eg5 motor  
26 domain with bound  $Mg^{2+}$  (green), ADP (C $\alpha$ s in white) and Arry-520 (PDB ID 6HKX; violet).  
27

28  
29 **B)** Structural superposition of the crystal structure of Eg5 motor domain (PDB ID 1II6; white  
30 cartoon) with the structure of the Eg5 motor domain (blue) in complex with Arry-520.  
31

32  
33 **C)** Helix  $\alpha$ 4, helix  $\alpha$ 5 loop L12 and the neck-linker region undergo conformational changes  
34 from the intermediate (cyan) to the final inhibitor-bound state (blue). Helix  $\alpha$ 4 moves to the  
35 permissive position to make space for the neck-linker, which subsequently adopts a docked  
36 conformation (blue).  
37

38  
39 **D)** Surface representation around the helix  $\alpha$ 2/ loop L5 / helix  $\alpha$ 3 allosteric pocket in the  
40 “closed” inhibitor bound state (inhibitor is not shown). Amino acid substitutions in the labeled  
41 amino acids within the pocket have been shown to confer resistance to various loop L5  
42 inhibitors in biochemical as well as cell based assays without affecting the binding of the  
43 inhibitors to the pocket (see Table II).  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**Figure 4** Structural superposition of the crystal structure of Eg5 motor domain (PDB ID 1II6; white cartoon) with the structures of the Eg5 motor domain (blue) in complex with allosteric inhibitors of the Loop L5 class that all bind to the helix  $\alpha$ 2/loop L5 / helix  $\alpha$ 3 pocket (PDB IDs: monastrol 1X88; (S)-enastron 2X7C; R-mon97 2IEH; STLC 2WOG; ispinesib 4AP0; SB 743921 4AS7; K858 6G6Y; EMD 534085 3L9H [165]; MK 0731 3CJO).

**Figure 5** Structural superposition of the crystal structure of Eg5 motor domain (PDB ID 1II6; white cartoon) with the structures of the Eg5 motor domain (blue) in complex with ATP competitive inhibitors that bind to the  $\alpha$ 4 and  $\alpha$ 6 pocket near but not in the ATP binding site (PDB IDs: GSK1 6TIW; PVZB1194 3WPN; BI8 3ZCW).

**Table I :** Eg5 inhibitors that entered clinical trials

Inhibitor	Sponsor	Phase	maximal tolerated dose	Elimination half-lives	Condition	Clinical trial / status	Published References
Arry-520	Array Biopharma	P1; P2	1.50 mg/m <sup>2</sup> /day	>90h	solid; MM,AML,MDS	NCT02384083 / unknown; NCT01372540 / completed NCT02092922 / completed ; NCT01989325 / completed NCT00637052 / completed ; NCT00462358 / completed NCT00821249 / completed ; NCT01248923 / completed	[109][110] [111][112] [113]
LY2523355	Eli Lilly	P1; P2	12 mg/m <sup>2</sup> /day	10-31h	solid, leukemia; ovarian,NSLCLC, PC,CRC, gastric, esophageal, HNSCC,BC, SCLC	NCT01358019 / completed ; NCT01416389 / completed NCT01214655 / terminated ; NCT01059643 / completed NCT01214629 / completed ; NCT01214642 / completed NCT01025284 / completed	[104][105]
4SC-205	4SC	P1	20mg/day	10h	solid , lymphoma	NCT01065025	[118]
ALN-VSP02	Alnylam	P1	1.0 mg/kg	10h	HCC	NCT01158079 ; NCT00882180	[78]
ispinesib	GSK	P1; P2	18 mg/m <sup>2</sup> //21 days	16h	Burkett Lymphoma; RCC,HNN, PC,ovarian BC, NSCLC,CRC, HCC, melanoma	NCT00354250 / completed; NCT00089973 / completed NCT00119171 / completed ; NCT00095628 / completed NCT00607841 / terminated ; NCT00363272 / completed NCT00097409 / completed ; NCT00098826 / completed NCT00136578 / completed; NCT00101244 / terminated NCT00096499 / completed ; NCT00085813 / completed NCT00095953 / completed ; NCT00095992 / completed NCT00103311 / completed; NCT00169520 / completed	[92][89] [90][91] [93][88]



AZD4877	AstraZeneca	P1; P2	11-18 mg	16h	solid, lymphoma, NHL; bladder, transitional, urethra, RCC	NCT00471367 / terminated ; NCT00661609 / completed NCT00613652 / completed ; NCT00486265 / terminated NCT00389389 / completed ; NCT00460460 / terminated	[97][98] [99]
SB-743921	Cytokinetics	P1; P2	4-6 mg/m <sup>2</sup>	29h	solid; NHL HL	NCT00343564/ completed ; NCT00136513 / completed	[95]
ARQ 621	ArQule	P1	280 mg/m <sup>2</sup> /week		solid	NCT00825487 / completed	[101]
MK-0731	Merck	P1	17 mg/m <sup>2</sup> /day every 21 days	6h	solid	NCT00104364 / completed	[102]

MM : multiple myeloma; AML : Acute Myeloid Leukemia; MDS : myelodysplastic syndrome; NSLCLC : Non-small-cell lung carcinoma; PC : prostate cancer; HNSCC : Head and Neck squamous cell carcinoma; BC : breast cancer; SCLC : small cell lung cancer; HCC : hepatocellular carcinoma; RCC : Renal cell carcinoma; NHL : Non-Hodgkin lymphoma; HL: Hodgkin lymphoma.

**Table II:** Amino acids in the motor domain of Eg5 linked to resistance to Eg5 inhibitors

<b>Eg5 residue</b>	<b>mutation</b>	<b>location</b>	<b>tested inhibitor resistance</b>	<b>Reference</b>
D130	A, K, V, G	Loop5	SB-743921, STLC, monastrol, Arry-520	[120][121][59][129][130]
A133	D, I, V, M, P	Loop5	SB-743921, ispinesib, STLC	[120][127][124]
L214	A	Helix- $\alpha$ 3	STLC, monastrol, Arry-520, ispinesib	[125][126][59][130][129][130]
Y104	C	$\beta$ 3/ Ploop	BRD9876	[65]
E123	K	Loop5	STLC	[121]
A334	V	$\beta$ 8	STLC	[121]
H354	R	Helix- $\alpha$ 6	STLC	[121]
A103	V	P loop	STLC	[121]
G268	V	Switch II helix	STLC	[122]
E116	A, D, R, L, V	Loop5	monastrol, STLC	[124][128]
E118	V, D, L, N	Loop5	monastrol, STLC	[124][128]
R119	A, L, E	Loop5	monastrol, STLC	[126][128][125]
W127	F, L, A	Loop5	monastrol, STLC	[126][128]
P131	A	Loop5	monastrol, STLC	[123]
L132	A	Loop5	monastrol, STLC	[126][130]
I136	A	Helix- $\alpha$ 2	monastrol, STLC	[126][130]
E215	A	Helix- $\alpha$ 3	monastrol, STLC	[126][130]
R221	A	Helix- $\alpha$ 3	monastrol, STLC	[126]
Y211	F, A, M	Loop5	monastrol, STLC	[126][128]
V210	A	Helix- $\alpha$ 3	monastrol, STLC	[126]
S120	P	Loop5	ispinesib	[120]



Figure 1





Figure 2










Figure 3










Figure 4




**Monastrol**




**(S)-enastron**




**(R)-monastrol-97**




**STLC**




**Ispinesib**




**SB743921**



**K858**




**EMD 534085**




**MK-0731**


Figure 5



**GSK-1**



**PVZB1194**



**BI8**